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Summary
Glioblastoma multiforme (GBM) is the most common and most aggressive
type of primary brain tumour. It is currently treated by a mixture of ionising
radiation and Temozolomide (TMZ) chemotherapy, however virtually all patients
experience disease recurrence and 75% die within two years of diagnosis.
Tumours which express elevated levels of the DNA repair protein O6-
methylguanine DNA methyltransferase (MGMT) have a particularly poor
prognosis, suggesting that levels of MGMT and the inefficacy of treatment are
linked.
MGMT is a “suicide” repair protein that binds irreversibly to a DNA adduct
(such as those caused by TMZ) and is destroyed by the proteasome once repair
has taken place. Therefore the ability of the cell to repair DNA damage relies on
the rate at which it can resynthesise MGMT. Previous research has shown that
reducing MGMT levels via promoter silencing increases the effectiveness of
treatment, however this causes toxicity in bone marrow stem cells and is
therefore unable to be used as a possible treatment option.
My preliminary data suggests that inhibition of mTOR signalling reduces the
steady state levels of MGMT without affecting mRNA levels, potentially making
them more sensitive to TMZ treatment. I am therefore using inhibitors of the
mTOR pathway and associated proteins, which have been selected via a novel
bioinformatic technique, to ascertain how these affect MGMT protein levels and
to determine whether a mixture of these inhibitors with DNA damaging agents
could be used to increase the efficacy of TMZ treatment.
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Chapter I
Introduction
11 Introduction
The term ‘cancer’ encompasses a broad range of diseases caused by the
uncontrolled proliferation of cells. There are currently over 200 distinct types of
cancer, each with different causes and symptoms, therefore requiring different
treatments. Cancers arising from cells in the brain are among the 20 most
commonly diagnosed types of cancer and yet have a very low survival rate, with
only 14.5% of men and 16.1% of women in the UK surviving 5 years or more
after diagnosis [1]. With over 3500 people dying of brain tumours in the UK
every year, new approaches are needed to increase the efficacy of treatment.
1.1 Glioblastoma multiforme
Glioblastoma multiforme (GBM) is a world health organisation (WHO)
classified grade IV astrocytoma. The WHO grading system describes how fast
the tumour is actively growing on a scale from 1 to 4; 1 being the slowest
growing tumours and 4 being the fastest growing. An astrocytoma is a type of
cancer that arises from glial cells, which are the star shaped cells that form a
supportive network for neurons. GBM is one of the most aggressive types of
primary brain tumour, and it is also the most common [2]. GBM occurs most
frequently in adults, with less than 9% occurring in children [3]. The tumours are
especially hard to treat, as they display extensive heterogeneity, both at the
cellular and molecular levels [4]. It is this heterogeneity that earned the tumour
its name ‘multiforme’.
There are two main types of glioblastoma; primary glioblastoma and
secondary glioblastoma. Here I will focus on primary glioblastoma, as secondary
glioblastomas are the result of metastasis of cancerous cells from a pre-existing
tumour and have different underlying mutations than the primary form. Primary
glioblastomas arise de novo in older patients with no prior history of glioma and
have a particularly poor prognosis. As with most brain tumours, the specific
causes are unknown, yet GBM tumours are characterized by oncogene
amplification of EGFR, CDKN2A deletions and PTEN mutations. These
mutations will be discussed in greater depth later in the chapter. Recent work by
2the Cancer Genome Atlas Research Network has begun to reveal the extent of
the genetic and chromosomal abnormalities that contribute to the aggressive
and treatment resistant nature of this tumour [5].
1.2 Signs and symptoms
Common symptoms of brain tumours include, but are not restricted to,
headaches, seizures and nausea. However, depending on the site of the
tumour, changes in behaviour and mood can also be experienced. Headaches
can be an early sign of brain tumours, especially if the headache fits the pattern
for raised intracranial pressure, is unremitting, arises in unexpected
circumstances or is accompanied by vomiting or neurological deficit [6].
The symptoms caused by GBM can be due to the increased pressure in the
brain caused by the tumour, but can also be caused by haemorrhage or the
development of oedema around the tumour. Oedema around the tumour is
caused by the aberrant and un-regulated formation of blood vessels during
tumour formation, which does not form a functioning blood brain barrier and
allows cerebrospinal fluid to leak in to the brain cavity [7]. Symptoms occurring
from physical pressure in the brain can sometimes, but not always, be reversed
by surgical removal [8]. Nausea can be an unpleasant symptom of GBM and
may have a variety of causes. It may arise as part of posterior fossa syndrome
(an unexplained neurological condition that arises after tumour removal surgery,
which can present itself with stroke-like symptoms) [9] but may also be caused
by raised intracranial pressure, yet it is also associated with seizures and
chemotherapy side effects. Anti-emetics can be used to treat nausea, and in
some more extreme cases tranquilizers may be used [2,9].
1.3 Diagnosis and tumour progression
Diagnosis of GBM is usually achieved through imaging using computerised
tomography (CT) or magnetic resonance imaging (MRI). The tumours will
appear during such scans as grey masses with areas of necrosis and
sometimes cysts at the centre. They may appear to have a capsule, but this is
3always an artefact of rapidly growing tumour cells and compressed brain. As
mentioned previously, adjacent brain can be swollen with peri-tumoral oedema,
which tends to spread along the white-matter tracts and can form a conduit for
the migratory tumour cells, which can be found many centimetres from the main
tumour mass. These migratory cells may form secondary masses. Therefore,
although glioblastomas may appear to arise in multiple locations, this usually
represents spread from a single tumour [10]. Spread in this way does not
respect boundaries between the lobes of the brain and spread across the
corpus callosum (the large area of white matter that links the left and right
cerebral hemispheres) is common. This pattern is common in malignant glioma
and the term ‘butterfly tumour’ is frequently used to describe a tumour that
spans both lobes in this fashion [10]. Although rare, GBM can also arise in the
cerebellum, brain stem and spinal cord. The tumours are highly heterogeneous
at a cellular level, with almost any size and shape of cell being seen, including
multi-nucleated giant cells, which are characteristic of glioblastoma. Although
spread of the tumour within the brain is common, systemic metastasis is rare
[11]. Diagnosis can be confirmed by biopsy of the tumour, but it is generally
good practice to resect as much of the tumour as possible during biopsy
retrieval, so as to assist with treatment and delay progression.
1.4 Current treatments
At present GBM is generally treated by surgical removal (where possible)
followed by two types of therapy: Ionizing radiation (IR) and chemotherapy [12].
The combination treatment is rigorous, yet prognosis is often poor and although
chemotherapy improves survival in a subset of patients, 75% die within 2 years
and the majority of patients experience disease recurrence [13].
Surgery has three main roles in brain tumour management: to obtain a
diagnosis, to contribute to survival and to relieve symptoms. For the resection of
a tumour, access is gained by craniotomy. A scalp incision is made and a flap of
skin and peri-cranial tissue lifted. The site of the craniotomy will depend on the
position of the tumour. Most surgeons prefer a free bone flap, which is created
4first by making burr-holes (small holes drilled in to the scull), freeing the dura
mater and then cutting the flap using a high-speed craniotome. The dura mater
is then opened only by an amount that will give adequate exposure of the
tumour-bearing brain. The size of the opening of the dura mater is restricted to
reduce possibility of infection. It is common practice to confirm the diagnosis
with an intra-operative frozen section or cytological smear, prior to performing
the full resection. The resection itself is normally performed by using a mixture
of sharp dissection, cauterisation and ultrasonic aspiration [14]. The aim is
always to remove as much of the tumour as is safely possible. The operation is
then completed with dural closure, replacement of the bone flap and skin
closure. This procedure can be performed while the patient is awake to allow for
‘cortical mapping’ of neurological function. Cortical mapping during the operation
can be used to avoid resection of brain tissue needed for important functions
such as speech, walking, movement, and memory [15].
Most radiotherapy is delivered using post-operative external beam X-rays.
However, various other techniques are possible, including intra-operative
radiotherapy and particle radiotherapy. In all situations the aim is to deliver a
maximal (or curative) dose to the entire tumour, whilst minimizing the normal-
tissue dose and volume [10].
For a chemotherapeutic drug to be effective it must be detrimental to tumour
growth and maintenance and be able to access to the tumour site. In the brain,
the intact blood-brain barrier generally inhibits the passage of molecules with
molecular weights greater than 200 Daltons. Drugs with a high partition
coefficient (nitrosoureas) or that are small (TMZ) can circumvent this barrier
[10]. Although in the vicinity of tumour the barrier is partially defective [9], large
hydrophilic molecules remain largely excluded from the tumour structures and
are not useful for therapy.
A standard chemotherapeutic agent used to treat GBM is TMZ. TMZ is used
as it is readily absorbed by the digestive tract due to its small size (194 daltons),
and also benefits from being acid stable, allowing oral administration [16]. The
5lipophilic character of TMZ allows it to cross the blood brain barrier, an important
factor for potential GBM chemotherapeutic compounds.
Once TMZ is absorbed in to the blood and exposed to a pH exceeding 7, it is
spontaneously broken down in to 5-(3-methyltriazen-1-yl)-imidazole-4-
carboxamide (MTIC). The dependence on pH makes TMZ an appealing
treatment for GBM, as brain tumors, in contrast to surrounding healthy tissue
often have an alkaline pH [17]. MTIC reacts with water and is then broken down
in to 4-amino-5-imidazole-carboxamide (AIC) and a methyldiazonium cation. It is
the latter that creates lesions at the N7 and O6 positions of guanine and the N3
position of adenine in DNA, the most lethal of these lesions is O6-methylguanine
[18].
Another chemotherapeutic that is commonly used to treat GBM is
procarbazine. It is also an alkylating agent, but unlike temozolomide,
procarbazine is metabolically activated in the liver. Although procarbazine is
used as a treatment option, its mechanism of action is not fully understood [19].
Procarbazine is usually administered in combination with vincristine. Vincristine
depolymerises tubulin polymers such as microtubules, which prevents mitosis
from taking place, promoting the process of apoptosis [20]. Countless other
chemotherapeutic options have been trialled, but none have been successful
enough to replace the current alkylating agents as a “gold standard” for
treatment.
An alternative treatment option is the use of the Gliadel® system. This
comprises a biodegradable polymer in wafer form that is impregnated with
carmustine. The mechanism of action of carmustine is discussed later in the
chapter. A number of these wafers are used to line the cavity left after resecting
a brain tumour. After wound closure the polymer slowly breaks down, delivering
the carmustine in a more concentrated fashion than is possible to achieve by
systemic delivery[21]. Although Gliadel® has been shown in prospective
randomized clinical trials to improve survival in patients undergoing surgery for
newly diagnosed and recurrent high-grade glioma, it is little used in the UK [21].
6As the effectiveness of the chemotherapeutic agents and their delivery are
problems which need to be resolved, new techniques are being developed to try
and address these issues. Convection-enhanced delivery (CED) is a new
surgical technique in which a thin catheter is placed into the brain and
connected to an extracranial, pump-driven syringe containing a
chemotherapeutic agent. By selecting an appropriate delivery rate, the
chemotherapeutic can be made to ‘flow’ directly into the tumour. This technique
can be used to deliver a variety of cytotoxic agents, including large molecules,
to regions in the brain remote from the catheter tip. This technique is currently
under investigation in large randomized clinical trials [22].
1.5 DNA damage and repair
The O6-methylguanine lesion is particularly cytotoxic if left unrepaired as it
results in a mispairing of guanine and thymine. This mispairing then activates
the mismatch repair (MMR) pathway [23,24], through recognition from hMutS
a DNA mismatch recognition protein. Upon recognition the daughter strand
opposite the lesion is then excised by hMutL and EXO1. Replication protein A
(RPA) then binds the single- stranded DNA to prevent it from folding back on
itself, while the X family DNA polymerase members, lambda and mu,
resynthesise the daughter strand [25]. However, because the MMR pathway
solely excises and inserts nucleotides in the daughter strand, the O6-
methylguanine on the template strand is left intact. This leads to a futile MMR
cycle of reinserting thymine, causing replication fork stalling, ATM/ATR
activation, and DNA double-strand breaks, eventually forcing the cell in to
apoptosis [18,26].
Radiotherapy utilises  rays to cause double-strand breaks in DNA. Double-
strand breaks in humans activates both the non-homologous end joining (NHEJ)
and the homologous recombination (HR) DNA repair pathways [27].
NHEJ repairs the double strand breaks by direct ligation of the broken
strands. The double-strand break sites are held in close proximity by the end
binding complex heterodimer, Ku (Ku70-Ku80), which forms part of the DNA
7dependent protein kinase (DNAPK). The end joining complex then recruits the
catalytic subunit of DNAPK (DNAPKcs) which then forms a complex with
Artemis and DNA ligase IV [28], which reattaches the broken ends. NHEJ is
often error prone, due to small insertions, deletions or substitutions at the break
site, or possibly translocations if two strands from different parts of the genome
are accidentally joined [28].
HR is initiated when the DSBs are recognised and then resected by
nucleases and helicases, generating a single-stranded DNA (ssDNA) overhang
onto which the RAD51 recombinase assembles as a nucleoprotein filament
(Fig.1.1). RAD51 then directs the strand to similar or identical sequences to use
as a template for repair. As HR generally only occurs in cells after DNA
replication there should be a sister chromatid to use as a template strand,
minimising the opportunity for error. In cells that favour non-crossover HR and
require only short inserts of DNA sequence, the RTEL helicase can be
expressed, inhibiting D-loop formation and encouraging synthesis-dependent
strand annealing (SDSA) [27]. If the RTEL helicase is not expressed, D-loop
formation occurs. This D-loop can then be cleaved which results in resolution. If
the D-loop is not cleaved a double Holliday junction can form (dHJ). Once
formed, the double holiday junctions can either be ‘migrated’ by topoisomerase
III, resulting in dissolution [29], or cleaved by endonucleases (resolvases),
which, depending on the cleavage site, can result in crossover or non-crossover
products.
1.6 ATM and ATR
Phosphatidylinositol-3-kinase related kinases (PIKKs) comprise a family of
serine/threonine protein kinases that show sequence similarity to the
phosphoinositide 3-kinase family. They contain the DNA damage repair proteins
ataxia telangiectasia mutated protein (ATM), ataxia telangiectasia and Rad 3
related protein (ATR) and DNAPK, as well as the mechanistic target of
rapamycin (mTOR). ATM regulates cell cycle checkpoints and DNA repair [30].
Activation of ATM by autophosphorylation on Ser1981 occurs as a response to
Figure 1.1 Schematic representation of homologous recombination pathway choices
The initial stages of HR are similar in all cells during all phases of the cell cycle. The double 
strand break is recognised, and the RAD51 recombinase accumulates on the 3’ overhang of 
the broken DNA. RAD51 then directs the strand to similar or identical sequences to use as a 
template for repair. In cells/phases where non-crossover HR that only inserts short sequences 
of DNA are favourable, the RTEL helicase can be expressed, inhibiting D-loop formation and 
encouraging SDSA. If this does not occur a D-loop forms. This D-loop can then be cleaved and 
result in resolution, or a double Holliday junction can form (dHJ). Once formed, the double holi-
day junctions can either be ‘migrated’ by topoisomerase III, resulting on dissolution, or cleaved 
by endonucleases (resolvases), which, depending on the cleavage site, can result ion crossover 
or non-crossover products. Adapted from Chapman et al. 2012. 
8exposed DNA double stranded breaks [31]. However, it has also been recently
suggested that ATM may also play a part in translational control and signalling
upstream of mTOR [30]. ATM has not only been implicated in inhibiting 4E-BP1
in response to insulin signalling, but also in activating Akt, thereby increasing
signalling through mTORC1. The increased signalling through mTORC1 can
result in increased rates of protein translation (see section on mTOR signalling
for further details).
During DNA replication and cellular stress, ssDNA often arises. This can be
caused by replication fork stalling, futile MMR cycles (as mentioned previously)
or lesions such as DNA crosslinks. ssDNA is bound by the ssDNA-binding
protein RPA, which in the canonical ATR signalling pathway, is the ligand that
recruits ATR and other ATR signalling components to sites of replication stress
[32].
As mentioned above, DNAPK comprises the Ku heterodimer, Ku70/80, and
the catalytic subunit DNAPKcs. Both the Ku heterodimer [33] and DNA-PKcs
[34] can bind directly to DNA, but, in the absence of Ku the affinity of DNA-PKcs
for DNA is greatly reduced [35]. As well as playing a role in actively repairing
double-strand breaks via NHEJ, DNAPK also phosphorylates p53 in response to
double strand breaks.
p53 has two known negative regulators, MDM2 and MDM4 (sometimes
known as MDMX). MDM2 acts by binding to the N-terminal end of p53 and
inhibiting the transcriptional activation function of p53 [36,37] (Fig.1.2). MDM2
also possesses E3 ubiquitin ligase activity that targets p53 for modification and
subsequent degradation through the 26S proteasome [38–40].
Ubiquitination is the reversible process of ‘tagging’ a substrate with ubiquitin.
This process guides proteins to different compartments of the cell, including the
proteasome, where proteins are broken down in to constituent amino acids. The
Ubiquitin system was discovered in 2004 by Aaron Ciechanover, Avram
Hershko and Irwin Rose [41], and consists of a three-step process whereby an
E1 ubiquitin-activating enzyme ‘charges’ an E2 ubiquitin-conjugating enzyme
with ubiquitin. An E3 ligase then binds both the E2 ligase and the substrate, an
Figure 1.2 Schematic representation of cell cycle arrest following DNA damage
Double strand breaks in DNA activate the PIKKs DNAPK, ATM and ATR. The activation of 
these proteins results in both the activation of DNA repair pathways and the activation of 
p53. p53 has two negative regulators; MDM2 and MDM4. DNAPK inhibits MDM2 whilst ac-
tivating p53, and ATM/ATR inhibit MDM4 whilst simultaneously activating p53. The proteins 
activated by p53 then lead to mTOR signalling inhibition (Figure 1.5) and cell cycle arrest 
at the G2/M checkpoint via the activation of GADD45 and p21 cip1/waf1, which then inhibit 
CDK1. 
9isoppeptide bond is then formed between the two [42,43]. The result of protein
ubiquitination can be degradation of the target by the proteasome, but can also
play a part in protein-protein interactions [44], depending on the amount of
ubiquitin added and where it is attached to the substrate. In humans, there are
currently 2 known genes that encode E1 ligases, 37 genes that encode E2
ligases, and over 600 genes that encode E3 ligases [45].
MDM4 binds p53 in a similar manner to MDM2, inhibiting the transcriptional
activity of p53. In response to DNA double-strand breaks and ssDNA, ATM,
ATR and DNAPK all phosphorylate p53. The phosphorylation of p53 impairs the
ubiquitin degradation ability of MDM2, allowing p53 stabilisation and activation
[46]. In addition to this DNAPK also phosphorylates MDM2, and ATM/ATR
phosphorylates MDM4, both events result in inhibition of the regulatory effects
of the proteins. The following activation/lack of inhibition of p53 can result in the
increased transcription of p21 cip1/waf1, which ultimately leads to inhibition of
the CDK1/cyclin b complex formation, resulting in G2/M cell cycle arrest [47],
allowing the cell time to repair DNA damage (Fig.1.2).
1.7 O6-methylguanine DNA methyltransferase
The DNA repair protein that is responsible for repairing the O6-methylguanine
lesion in DNA is O6-methylguanine DNA methyltransferase (MGMT). MGMT
repairs the cytotoxic lesion created by methylating agents such as TMZ (but
also environmental pollutants such as tobacco-specific carcinogens) [48] by
transferring the methyl group on the DNA to a cysteine acceptor site in the
MGMT protein itself (Fig.1.3). This reaction is irreversible and once bound to the
alkyl group, the MGMT protein is ubiquitinated and destroyed by the
proteasome [49]. The success of TMZ chemotherapy therefore relies, in part, on
the ability of the tumour to re-synthesise MGMT and maintain steady state
levels of the protein.
Genetic profiling of GBM in some patients is currently used to predict the
outcome of TMZ chemotherapy. It has been shown that if a tumour contains
cells with a methylated MGMT promoter (and therefore lacking MGMT protein),
Figure 1.3 Schematic representation of the DNA repair function of MGMT
MGMT removes methyl adducts in DNA by transferring the methyl group on the DNA to 
a cysteine acceptor site in the MGMT protein itself in a stoichiometric reaction. Once the 
MGMT protein has undergone this reaction, it is unbiquitinated and degraded by the protea-
some. MGMT is known as a suicide repair protein, as it can only repair one methyl adduct 
before being degraded. 
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this can be correlated to enhanced survival of patients treated with TMZ [50].
However, only around half of GBM tumours exhibit MGMT promoter
methylation, and prognosis is still poor for those with an unfavourable genetic
status [51,52].
1.8 MGMT protein expression
MGMT protein expression is controlled by both transcriptional and post-
transcriptional mechanisms. MGMT is known to be positively controlled by the
transcription factors, SIP1 and NFκB [53]. It has been suggested that SIP1 can 
be sequestered by p53 during DNA damage, preventing the transcription of
MGMT, which could aid in the efficacy of DNA methylating agents. However,
this may not occur in cancerous cells as p53 is often poorly expressed [54]. The
methylation of the MGMT promoter can also inhibit its transcription, leading to
reduced amounts of MGMT protein expression [55,56].
Alternative splicing of genes is an important mechanism of post-
transcriptional regulation which can generate different transcripts from a single
pre-mRNA. MGMT has multiple predicted splice variants, yet these have limited
support in the scientific community [57], and further work will need to be carried
out to explore these possibilities. The expression of MGMT protein varies
across tissues in the body, with tissues that are exposed to a higher degree of
carcinogens and environmental damage such as the digestive tract, liver, skin
and lungs showing moderate amounts of the protein expressed. On the other
hand, cardiac tissues and the central nervous system (which should be
exposed to environmental damage at a lower frequency) show much lower
levels of MGMT protein expression [48]. Although increased methylation of the
promoter region of DNA encoding MGMT is strongly correlated with decreased
MGMT protein levels [55], MGMT levels in cells lacking a methylated promoter
show varying degrees of MGMT protein expression. These data suggest that
MGMT protein may also be regulated in a post-transcriptional fashion. Coupled
with this, research has suggested possible miRNA binding sites in the MGMT
mRNAs 3’UTR, again suggesting an additional regulatory mechanism [58]. It is
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clear that the mechanisms underlying MGMT expression are not fully
understood, and this should be of upmost importance, as MGMT is undoubtedly
a hurdle in successful cancer treatment.
1.9 Modulating levels of MGMT in GBM
Attempts have been made at modulating levels of MGMT protein in GBM
cells. Adenovirus based gene therapy directed at methylating the MGMT
promoter in GBM cells resulted in a positive outcome in mice xenographs [59].
In spite of this success adenoviral gene therapies in GBM patients are difficult to
administer, and often fall short of expectations during clinical trials [60].
Before TMZ became widely available as a treatment in the late nineties,
carmustine, a nitrosourea that is both an alkylating agent and causes DNA
crosslinks was used as a chemotherapeutic treatment. Carmustine only
increased survival by approximately 2 months when used alone [61], however,
when used in conjunction with direct MGMT protein inhibitors such as O6-
benzylguanine, which binds to the active site of MGMT, this combination
sensitised tumours to alkylating agents. However, this combination was also
cytotoxic to cells with a long self-renewal period (such as haematopoietic stem
cells which replicate approximately every 40 weeks [62]), in a dose limiting
manner [63]. To avoid cytotoxicity when combining TMZ and O6-benzylguanine
in GBM, O6-benzylguanine has been administered directly to surgical cavities
after tumour resection. However, as surgery is not always possible, alternative
therapies need to be developed to reduce levels of MGMT protein in GBM
tumour cells [64].
1.10 Common mutations in GBM cells
Common mutations in GBM cells include mutations in the tumour suppressor
protein p53 [65], amplification of epidermal growth factor receptor (EGFR) [66]
and loss of phosphatase and tensin homolog (PTEN) function [67,68] (Fig.1.4).
The amplification of EGFR and the loss of PTEN can result in the hyperactivity
of PI3K/mTOR signalling (Fig.1.5). Another common mutation in GBM is an
Figure 1.4  Diagram representing common mutations found in GBM
Many genetic mutations arise in cancer cells, these can often result in amplifications of pro-
proliferation genes, and deletions of pro-apoptotic genes. This is an example of some of the 
most commonly mutated genes in GBM tumours, that can directly influence mTOR signalling 
and therfore growth and proliferation. Adapted from Shinji & Tanaka, 2013. 
Figure 1.5 Schematic representation of the mTOR signalling pathway and associated proteins
The mTOR signalling pathway integrates signals from extracellular signalling molecules, hypoxia, glucose signalling and amino acid sensing.
Pathway key
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amplification of Met, which encodes the hepatocyte growth factor receptor
(HGFR), an RTK that is usually only expressed in epithelial cells [69]. This
amplification not only causes hyperactive signalling through ERK and PI3K
pathways, but also drives angiogenesis. In addition to the amplification of
numerous signalling proteins, GBM exhibits a mutation of FOXO in 1% of cases
(Fig.1.4). The FOXO proteins are a family of transcription factors that are known
to promote expression of pro-apoptotic proteins, but have also been observed to
mediate some protein-protein interactions [70].
As cancerous cells can become reliant on hyperactive pathways driven by
mutations, in a process known as oncogenic addiction [71], they offer a possible
target for cancer treatments. The concept of oncogenic addiction is appealing
not only because it provides a rationale for directly targeting hyperactive
pathways in cancerous cells, leading to cell growth inhibition and possibly
apoptosis, but also selectively targeting cancerous cells, as healthy cells would
be able to overcome pathway inhibition by using an alternative mechanism.
1.11 mTOR signalling
Schreiber et al. first identified the mTOR protein in 1994 [72] as the target of
the macrolytic fermentation product of the bacterium Streptomyces
hygroscopicus, rapamycin. Rapamycin gained its name from the island from
which it was first obtained in a soil sample in 1975 (Rapa Nui [73,74]) and it
sparked considerable interest due to its antiproliferative effects.
mTOR belongs to the PI3K-related kinase family of proteins and is involved in
the regulation of the phosphorylation of downstream targets such as p70S6K
and 4E-BP1 by: mitogens; extracellular signalling molecules; glucose
availability; hypoxia; and amino acid availability. The mTOR pathway responds
to these signals by regulating essential cellular functions, such as protein
synthesis, lipid synthesis, autophagy, lysosome biogenesis, energy metabolism,
cell survival and cytoskeletal reorganisation [75] (Fig.1.5).
The mTOR protein is currently known to interact with several proteins to form
two distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2) [75].
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mTORC1 contains six know proteins, and mTORC2 contains seven. Both
mTOR complexes share the mTOR protein, mammalian lethal with sec-13
protein 8 (mLST8) [76,77], DEP domain containing mTOR-interacting protein
(DEPTOR) [78] and the Tti1/Tel2 scaffold protein complex [79]. The two
remaining proteins that participate in mTORC1 are the regulatory-associated
protein of mammalian target of rapamycin (raptor) [80,81], which is responsible
for the sensitivity of mTORC1 to rapamycin, and the proline-rich Akt substrate
40 kDa (PRAS40) [82]. In addition to the four proteins that mTORC2 shares with
mTORC1, it also contains the rapamycin-insensitive companion of mTOR
(rictor), the mammalian stress-activated map kinase-interacting protein 1
(mSin1) and the protein observed with rictor 1 and 2 (protor1/2) (Fig.1.5). The
regulation of mTORC1/2 signalling is described below.
1.12 ERK1/2 signalling cascade
The extracellular signal-regulated kinase 1 and 2 (ERK1/ 2) signalling
pathway can be activated by G-protein coupled receptors (GPCRs), integrin
receptors and most commonly, receptor tyrosine kinases (RTKs) [83]. Growth
factors are extracellular signalling molecules such as cytokines, mitogens and
hormones. The 44-kDa ERK1 and 42-kDa ERK2 proteins were the first MAPKs
to be discovered to take part in a MAPK cascade [84].
In general, growth factor binding activates RTKs by inducing receptor
dimerisation [85]. The dimerisation of the extracellular RTK domain then causes
the phosphorylation of a tyrosine residue on the cytoplasmic portion of the
receptor [86]. The phosphorylated tyrosine residue activates the Src homology 2
(SH2) domain on the growth factor receptor-bound protein 2 (Grb2), this in turn
causes a conformational change in the Src homology 3 (SH3) domain of Grb2,
increasing its binding affinity and allowing it to bind to the guanine nucleotide
exchange factor, son of sevenless (SOS). The interaction of Grb2 with SOS
then causes the membrane recruitment of this complex bringing the guanine
nucleotide exchange factor in close proximity to Ras, resulting in GTP exchange
on Ras and hence its activation (reviewed in [87]). Ras then transmits the signal
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by activating the protein kinases Raf-1, B-Raf, and A-Raf (Rafs). Once
activated, the Raf family of MAPKKKs specifically activates two MAPKKs,
MAP/Erk kinase 1 (Mek1) and Mek2, which in turn selectively activate Erk1 and
Erk2. Erk1 and Erk2 are nearly 85% identical overall, with much greater identity
in the core regions mediating the binding of substrates [88].
The activated ERK1/2 inhibits tuberous sclerosis protein 1 and 2 (TSC1/2).
TSC1/2 are GTPase-activating proteins that act on Ras Homolog Enriched in
Brain (Rheb). As Rheb directly activates mTORC1 when GTP bound, TSC1/2 is
a negative regulator of mTORC1, meaning that TSC1/2 inhibitors are activators
of mTORC1 [89](Fig.1.5). As well as its direct influence on the mTORC1
signalling pathway, ERK1/2 also targets transcription factors such as, Elk1 [90],
c-Fos [91] and c-Jun [92]. ERK1/2 signalling can also be extended by the
phosphorylation of MAPK-activated protein kinases (MAPKAPKs). The first
MAPKAPK to be discovered was p90RSK, which is phosphorylated and
activated by ERK1/2 and PDK1 at multiple sites, encouraging further inhibition
of TSC1/2, and therefore mTOR activation [93]. MAPK-interacting protein
kinase (Mnk) [94,95] and mitogen and stress-activated protein kinase (MSK)
were also identified as MAPKAPKs of the cascade [96]. However, the activation
of these kinases is not restricted to the ERK1/2 cascade, as they are also
activated by the p38 cascade, mainly under stress conditions [97].
Ras and Raf are commonly mutated in cancerous cells, propagating
signalling even in the absence of growth factors, suggesting the ERK1/2
signalling cascade could be important in cancer development [98,99].
1.13 p38 MAPK signalling
The p38 MAP kinases are a family of stress-activated MAP kinases that
contribute to the regulation of cell proliferation and autophagy. Although the p38
MAPK cascade is similar in organisation to the ERK1/2 signalling pathway (as it
is a MAPK signalling cascade), it is less well characterised. The signalling
cascade can be triggered by stress, DNA damage and growth factor binding.
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The signal is propagated by many upstream MAPKKKs responding to distinct
stimuli which include: mixed lineage kinases (MLKs); transforming growth factor
activated kinases (TAKS); and apoptosis stimulating kinases (ASKs) [83].
These proteins then phosphorylate and activate three MAPKKs (MAPKK3,
MAPKK4 and MAPKK6) that phosphorylate and activate p38 MAPKs [100,101].
Four p38 MAPK isoforms have been identified () that differ between
organisms and tissues [102]. p38 MAPK is important in respect to translation
initiation, as it has been shown to phosphorylate and activate the MAPK
interacting proteins Mnk1/2. This will be explored further on in this chapter in
respect to eIF4E phosphorylation and translation.
1.14 PI3K signalling
Phosphatidylinositol-3-kinases (PI3Ks) are a group of lipid kinases that can
be split in to 3 classes. The class I PI3Ks can then be further subdivided in to
class IA and class IB. Class IA, encompassing the catalytic subunit isoforms
p110α, p110β and p110δ, associate with the regulatory subunits p85α, p85β, 
p55α, p55γ and p50α whereas the class IB PI3Ks, consisting only of the p110γ 
catalytic subunit, binds the regulatory subunits p101, p84 and p87PIKAP [103].
The class II PI3Ks do not contain regulatory subunits, and purely consist of the
catalytic subunits C2α, C2β and C2γ [104]. The class III PI3Ks contain only one 
protein, PIK3C3, whose function in mammals is still unclear but are known to
have a role in nutrient regulation of mTORC1 and autophagy [105]. I shall refer
to the class IA PI3Ks as the representative isoforms of PI3K in this instance.
The PI3K signalling pathway is primarily activated through growth factor
binding to RTKs, but can also be activated via GPCRs [106]. Growth factor
binding results in autophosphorylation of the RTK on its intracellular tyrosine
residues, providing a sequence-specific binding site for the p85 regulatory
subunit of PI3K via its SH2 domain, which sequesters the p85 subunit from the
p110 catalytic subunit. In the absence of upstream signals, the regulatory
subunit stabilises the p110 subunit and suppress its catalytic activities. If the
p85 subunit is docked to phosphotyrosine, a conformational change allows for
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p110 to phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) to produce
phosphatidylinositol (3,4,5)-triphosphate (PIP3) which functions as a second
messenger. This process can be reversed by the tumour suppressor protein
PTEN, which is often mutated in GBM [107]. PDK1 is a serine/threonine kinase
containing a C-terminal pleckstrin homology (PH) domain [108], which binds to
PIP3 with high affinity, thereby recruiting PDK1 to the inner plasma membrane.
Upon membrane recruitment, PDK1 phosphorylates Akt at its Thr308 site,
stimulating its kinase activity [109,110]. Activated PDK1 is also required for the
activation of p90RSK. Akt possesses an N-terminal PH domain which recruits
the kinase to PIP3, a central kinase domain, and a carboxy-terminal
hydrophobic regulatory domain. To be fully activated, Akt also needs to be
phosphorylated on its Ser473 site, which can be phosphorylated by the
mTORC2 complex [111,112]. Once activated, Akt phosphorylates (therefore
inhibits) TSC1 and TSC2 which allows activation of mTORC1 and its
downstream effectors. Akt activation also phosphorylates and inhibits GSK3
[113], which is important in a translational context, as GSK3 (when active),
phosphorylates eIF2B, inhibiting its GEF activity. The inhibition of GSK3
therefore stimulates guanine nucleotide exchange on eIF2 and thus the process
of translation initiation (see further on in the chapter for details).
1.15 Wnt signalling and mTOR
The Wnt signalling pathway also interacts with the mTOR pathway (Fig.1.5).
This interaction is primarily through glycogen synthase kinase 3 (GSK3), which
has been suggested to be inhibited following phosphorylation by Akt when the
PI3K pathway is active [114,115]. The Wnt signalling pathway is activated by
binding of a Wnt protein to a 7 transmembrane receptor in the frizzled family of
proteins [116]. Upon ligand binding, frizzled phosphorylates dishevelled (Dsh)
which in turn inactivates GSK3. The inactivation of GSK3 prevents
phosphorylation of TSC2, an event that also requires priming from AMP-
activated protein kinase (AMPK) [117]. Active Wnt signalling therefore promotes
mTORC1 signalling.
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1.16 Glucose regulation and hypoxia
AMPK is composed of three subunits, regulatory and  subunits, and a
catalytic  subunit. During reduced cellular ATP levels, ADP or AMP binds the 
subunit of AMPK, promoting phosphorylation at Thr172 on the  subunit by the
upstream kinase LKB1 and protecting the protein from dephosphorylation
[118,119]. Reduced glucose [120] and oxygen [121] levels can result in an
increase cellular AMP levels. The activation of AMPK both phosphorylates
TSC1/2 and inhibits the raptor component of the mTORC1 complex, therefore
inhibiting mTORC1 signalling [122] (Fig.1.5).
1.17 DNA damage
Although the effect of DNA double-strand breaks in cell stress and cancer
has already been discussed, it is important to note that as well as possessing
the ability to halt the cell cycle, p53 also directly influences proteins in the
mTOR signalling pathway (Fig.1.5). In response to DNA damage or acute
cellular stress such as hypoxia, transcriptional expression of regulation of DNA
damage response 1 (REDD1) is induced by p53. The REDD1 protein then
interacts with TSC1/2 in a poorly understood mechanism [123], leading to
inhibition of mTORC1 signalling. As well as the expression of REDD1, upon
activation, p53 also induces the expression of sestrin1/2 which directly activates
AMPK[124]; this in turn activates TSC1/2, therefore inhibiting mTOR
signalling.
1.18 Amino acid sensing
The availability of amino acids also affects mTOR signalling and downstream
events. mTORC1 activation requires the presence of amino acids to be
activated by any upstream signals [125]. Until recently, the molecular
mechanism through which mTORC1 senses intracellular amino acids remained
a mystery, but what has become clear is that amino acid dependent activation
of mTORC1 is TSC1/2 independent [126], and requires a group of GTPases
known as the Rag GTPases [127,128], functioning in a complex known as the
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“ragulator”. Humans have four Rag proteins that form heterodimers as either
RagA/B or RagC/D. The two members of the heterodimer have opposite
nucleotide loading states, so that when Rag A/B is bound to GTP, Rag C/D is
bound to GDP and vice versa [75]. Amino acids promote the loading of the Rag
heterodimers with GTP, which then directly interacts with the raptor protein
within the mTORC1 complex, promoting eukaryotic translation [128]. Little is
known about the exact mechanism by which mTORC1 senses amino acid
sufficiency, but evidence suggesting that mTORC1 is recruited to the surface of
the lysosome by the Rag GTPases, where it is then activated by membrane
localised Rheb [127,129].
1.19 Downstream targets of mTORC1
Many pathways converge at the activation of the mTORC1 complex, it is
therefore unsurprising that the regulation of mTORC1 is not only important in
relation to cap dependent translation (as discussed below), but that the complex
is also involved in regulating other processes such as ribosomal subunit
synthesis [130] and autophagy [131,132]. The activation of mTORC1 directly
results in phosphorylation of p70 S6K at its Thr389 site. P70 S6K is a serine
threonine kinase that, when active, phosphorylates multiple residues in the
carboxyl terminal region of the ribosomal S6 protein (Ser235, Ser236, Ser240,
and Ser244). These phosphorylation events have previously been thought to
positively control the translation of mRNAs containing 5’ terminal oligopyrimidine
tracts (TOPs), yet contradictory evidence dismissing this theory has also been
found [133].
mTORC1 activation has also been shown to play a role in the regulation of
autophagy. When mTORC1 is active, it phosphorylates ATG13, which inhibits
autophagy. However, during reduced signalling through mTORC1, ATG13 is not
phosphorylated, and this thereby triggers autophagy [134]. Autophagy is also
regulated by a plethora of signalling proteins under different conditions (Fig.1.6),
for example, during reduced ATP levels, autophagy is both induced by reduced
mTORC1 signalling, and through the activation of p27 by AMPK[135,136].
Figure 1.6  Schematic representation of the regulation of autophagy
Autophagy in mammalian cells is regulated by a variety of signalling proteins. In nutrient rich conditions, mTORC1 phosphorylates ATG13, directly inhibit-
ing autophagy. Autophagy can also be activated by low ATP levels, amino acid deprivation, viral infection and ER stress. 
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Autophagy is also induced by the phosphorylation of eIF2and the resulting
activation of ATG12 (Fig.1.6), which can occur by activation of one or more of its
kinases; these kinases are discussed in detail later in the chapter. The tumour
suppressor, p53 plays a dual role in autophagy regulation. During cellular stress
p53 is stabilised and congregates in the nucleus where it acts as a transcription
factor, increasing the expression of pro-autophagic proteins such as DRAM1
[137]. However, when present in the cytoplasm, basal levels of p53 negatively
regulate autophagy [138]. The class III PI3K have also been implicated in the
induction of autophagy, but this link still needs to be researched in greater depth
[139].
1.20 Cap dependent initiation of translation
Eukaryotic protein translation is carried out in three main stages; initiation,
elongation and termination, with the initiation stage generally accepted as a
major site of regulation of gene expression [140–143]. During the initiation
phase the ribosome binds to the mRNA and forms an 80S initiation complex at
the initiation codon. The elongation stage involves the ribosome catalysing the
synthesis of a polypeptide chain by the sequential addition of one amino acid
after the other as encoded by the mRNA until the termination codon is reached.
The termination stage includes the steps that are needed to release the
completed polypeptide chain and dissociate the mRNA from the ribosome.
The initiation stage of protein translation is an intricate process mediated by a
group of proteins known as eukaryotic initiation factors (eIFs) [144–147]. The
processes involved in initiation can be sub-divided in to four individual events:
recruitment of Met-tRNA to the 40S ribosomal subunit, recruitment of the 43S
pre-initiation complex to the mRNA, scanning of the mRNA by the ribosome and
60S ribosomal subunit joining (Fig.1.7).
1.21 Recruitment of Met-tRNA to the 40S subunit
The first stage of the initiation process is mediated by eIF2, a G-protein that
comprises three subunits (, and ). The  subunit of eIF2 mediates Met-tRNA
Figure 1.7 Schematic representation of eukaryotic translation initiation and ribosome 
 binding
The binding of mRNA to the ribosome occurs in many stages. The 40S subunit (already bound 
to eIF3, eIF4B, eIF1 and eIF1A) interacts with eIF2-GTP-Met-tRNA to form the 43S preinitia-
tion complex. This is then bound by the eIF4F initiation complex, which aids in the scanning of 
the structured 5’ UTR of the mRNA until the start codon is recognised by eIF1, forming the 48S 
initiation complex.  Once the start codon is recognised, eIF2 bound GTP is hydrolysed and par-
tially lost. This then paves the way for 60S subunit and eIF5B-GTP binding, which displaces the 
other initiation factors, allowing 80S subunit formation and subsequent protein synthesis. 
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binding [148–150] and contains the main docking site for GTP/GDP. The 
subunit is important for the interaction with eIF2B, and the  subunit contains
the phosphorylation site (Ser51) which controls the activity of the protein
[151,152]. The binding of Met-tRNA requires eIF2 to be in its active, GTP-bound
state. As the non-enzymatic guanine-nucleotide-exchange reaction is very slow,
it requires catalysis by eIF2B. Although eIF2B shows little similarity to other
GTP-exchange proteins, it is classed as a GEF [153]. eIF2B comprises five
subunits: , , , ,  which are divided into a catalytic subcomplex (,) and a
regulatory subcomplex (,,) [154]. The  subunit of eIF2B interacts with the 
subunit of eIF2, facilitating the recruitment of eIF2 to the GEF and allowing
guanine nucleotide exchange to occur [152]. eIF2B can also be
phosphorylated, and its phosphorylation state can affect the GEF activity of
eIF2B [153,155]. Phosphorylation of eIF2 at Ser51 does not directly inhibit its
function, but increases the affinity of eIF2/GDP for binding to the regulatory
subcomplex of eIF2B, inhibiting its GEF activity. However, when eIF2 is GTP
bound, it associates with a molecule of Met-tRNA producing a ternary complex
(TC). As well as the roles detailed later in the chapter, eIF5 has also been
described as a GDP dissociation inhibitor for eIF2 [156], suggesting another
step in eIF2 regulation.
Four eIF2 kinases have been identified in mammals that phosphorylate
eIF2 at its Ser51 residue. These kinases are activated by different types of
cellular stress to inhibit translation initiation. Viral infection activates protein
kinase R (PKR), haem deprivation and oxidative stress activate haem-regulated
inhibitor (HRI), endoplasmic reticulum stress (ER) activates PKR-like ER kinase
(PERK) and nutrient deficiency/UV stress activates general control non-
depressible kinase 2, (GCN2) [157].
PKR is activated by the presence of double-stranded RNA (dsRNA), which is
produced as an intermediate of viral infection. As well as inhibiting translation
through eIF2 PKR activates several pro-inflammatory and pro-apoptotic
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transcription factors [158–160] and the expression of genes encoding
components of the death-inducing signalling complex (DISC) [161,162].
GCN2 has been shown to be activated by accumulation of uncharged tRNAs
during amino acid starvation [163], and as such inhibits translation via eIF2.
GCN2 has also been observed to become active following incubation of cells
with proteasomal inhibitors such as MG132, suggesting an alternative role in
ubiquitination or degradation of proteins [164].
PERK is a transmembrane protein which has both an ER-lumenal sensor
domain and a carboxy-terminal cytoplasmic protein kinase domain. In non-
stressed cells, the luminal domain of PERK is bound to an abundant ER
chaperone, GRP78 (also known as BiP), thus keeping PERK inactive. During
ER stress, unfolded proteins accumulate in the ER, resulting in GRP78
dissociating from PERK to bind to the unfolded proteins. The dissociation of
GRP78 from PERK leads to activation of the cytoplasmic domain and
phosphorylation at its Thr980 site [165,166], resulting in phosphorylation of
eIF2 at the Ser51 site, inhibiting protein synthesis. The activation of PERK via
the unfolded protein response is the most commonly studied mode of activation,
yet is not the only one. PERK activation has also been observed in pancreatic 
cells during low glucose concentrations, brought about by sarcoplasmic/ER
Ca2+-ATPase (SERCA) pump inhibition, which results in reduced levels in Ca2+
in the ER lumen [167].
1.22 Recruitment of the 43S pre-initiation complex to the mRNA
When the ternary complex containing eIF2/GTP and Met-tRNA has been
formed, it then associates with the 40S ribosomal subunit, eIF3, eIF1A, eIF1
and possibly eIF5 to form a 43S pre-initiation complex (Fig.1.7) [143,168,169].
eIF3 is a large complex with at least 13 different subunits which stabilises the
binding of Met-tRNA-eIF2-GTP to the 40S ribosomal subunit, prevents
premature binding of the 60S ribosomal subunit [168] and also promotes the
dissociation of the 40S and 60S ribosomal subunits[170]. During recruitment to
the mRNA, eIF3 also physically interacts with eIF4G, localising the 40S
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ribosome to the mRNA [171]. The large amount of non identical subunits that
comprise eIF3 and their possible individual functions make it an interesting topic
for research, for a detailed review of the multiprotein complex, see review [172].
The 43S complex is competent to bind mRNA non-specifically by itself.
However, assembly at the 5’ end of the mRNA requires the cap-binding
complex, eIF4F. Eukaryotic initiation factor 4F (eIF4F) is a multi-protein complex
comprising eIF4E, eIF4A and eIF4G, which is often deregulated in tumour cells
(Fig.1.8) [75,140,142].
Mammalian eIF4A is a 46-kDa protein that exhibits bi-directional RNA
helicase activity [173–176], which is negatively regulated by PDCD4 [177]. The
phosphorylation of PDCD4 by p70 S6K [178,179] results in its ubiquitination and
degradation, allowing eIF4A to participate in the eIF4F complex where its
activity is enhanced by eIF4B, eIF4H and eIF4G [144,180]. It has been shown
that the phosphorylation of eIF4B at its Ser406 and Ser422 sites is essential for
its positive influence of eIF4A activity, and therefore in protein translation [181].
It has also been recently shown that p70 S6K can phosphorylate eIF4B [179],
suggesting yet another link between mTORC1 signalling and cap-dependent
translation. Using ATP, eIF4A unwinds mRNA in the 5’ UTR of mRNA to allow
40S ribosomal subunit binding [173]. There are currently three known
mammalian isoforms, eIF4AI, eIF4AII and eIF4AIII [182,183], yet only eIF4AI
and eIF4AII have been observed in vivo to partake in protein synthesis [176].
Although no evidence has yet be found to support the role of eIF4AIII in protein
synthesis, it has been identified as a component of the exon junction complex
(EJC) [184]. The EJC is extremely important as it acts as a regulatory
checkpoint during translation of mRNA. The EJC binds to the exon join sites
(after splicing has occurred) in mRNA and if the mRNA has not been formed
correctly, and a nonsense mutation is identified before reaching the EJC,
nonsense mediated decay of the mRNA occurs.
eIF4G is a large protein that serves as a scaffold during translation initiation,
binding to eIF4A, eIF4E, eIF3, poly(A)-binding protein (PABP) and mRNA.
Three forms of the protein have been identified to date, eIF4G1, eIF4G2 and
Figure 1.8 Schematic representation of eIF4F formation and mRNA circularisation
Activation of mTORC1 phosphorylates 4E-BP1 which prevents it binding to eIF4E enabling 
eIF4E to bind eIF4G and participate in the formation of the eIF4F initiation complex (eIF4E, 
eIF4A, eIF4G) along with the poly (A)-binding protein (PABP) and eIF4B. The eIF4F initia-
tion complex binds to the m7 GTP cap at the 5’ end of mRNA and mediates small ribosomal 
subunit binding.
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eIF4G3. Whilst eIF4G1 and eIF4G2 are structurally similar, and both play a part
in cap-dependent translation, eIF4G3 has been implicated in alternative
ribosomal entry during cellular stress [185,186]. The N-terminal fragment of
eIF4G interacts directly with eIF4E [187–189] and PABP [188,190–192],
whereas the central region of eIF4G contains binding sites for eIF4A [193] and
eIF3 [194] and possesses RNA-binding activity [195]. The C-terminal domain of
eIF4G contains a second, independent binding site for eIF4A and a conserved
region at the extreme C-terminus of eIF4G, which has been shown to interact
with Mnk1/2 and suggested to interact with eIF5 and eIF2B [152,196]. The C-
terminus of eIF4G also contains phosphorylation sites at Ser1108, Ser1148, and
Ser1192 [197], which PKC has recently been implicated in phosphorylating, this
inhibits the interaction between eIF4G and Mnk1/2 [198]. Alongside serving as a
scaffold for the assembly of the translational machinery, eIF4G has also been
shown to increase the binding affinity of eIF4E for the mRNA cap [199] and to
increase the helicase activity of eIF4A [200]. eIF4G contains a HEAT domain
[201], and has been observed to be cleaved by picornavirus, therefore inhibiting
cap-dependent translation initiation [202].
eIF4E is a 25-kDa protein that is highly conserved from yeast to humans
[203,204]. Given its key role in the formation of the eIF4F initiation complex, it is
not surprising that it has been the subject of much discussion. There is currently
only one known phosphorylation site on eIF4E, Ser209, which has been
observed to become phosphorylated in response to cellular stress, and growth
factor stimulation of cells [205–209]. The phosphorylation of eIF4E is mediated
by Mnk1/2 [210–213]. The Mnk proteins bind to the C-terminus of eIF4G and
only phosphorylate eIF4E in cis, which means that phosphorylation only takes
place if the eIF4E is bound to the same eIF4G [143]. Although the
phosphorylation of eIF4E has previously been thought to be essential for
translation to occur, double-knockout mice with a mutated eIF4E
phosphorylation site do not exhibit a negative phenotype, suggesting that this is
not the case [214]. However, it has been observed that excessive eIF4E
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phosphorylation can promote malignancies possibly through enhanced export of
selected mRNA into the cytoplasm [215].
The formation of the eIF4F complex relies on the availability of eIF4E to
participate. Using a conserved motif, 4E-BPs (eIF4E-binding proteins) compete
with eIF4G for a common surface on eIF4E. This binding of eIF4E to 4E-BPs
therefore inhibits eIF4E from participating in eIF4F assembly, resulting in the
inhibition of cap-dependent ribosome recruitment to the mRNA [216] (Fig.1.7).
In mammals, three 4E-BP isoforms have been identified so far; 4E-BP1, 4E-
BP2, and 4E-BP3 [217–219], the most studied of which is 4E-BP1.
Hypophosphorylated 4E-BP1 binds efficiently to eIF4E, reducing the
availability of eIF4E for the translation initiation process. In contrast, multisite
phosphorylation of 4E-BP at Thr37/46, Ser65 and Thr70 inhibits this interaction,
allowing initiation complex assembly [144,197]. The phosphorylation of Thr37/46
by mTORC1 is thought to prime 4E-BP1 for subsequent phosphorylation at
Ser65 and Thr70 [144] (Fig.1.8). 4E-BP1 contains two important motifs that are
specifically bound by either raptor or mTOR. The TOS motif present on the C
terminus of the protein is bound by raptor, and the RAIP motif on the N terminus
is bound by mTOR, both motifs require binding to promote phosphorylation at
the multiple residues on 4E-BP1 and therefore it’s full activation [220].
Activation of mTORC1 phosphorylates 4E-BP1 and p70 S6K1
(S6K1)(Fig.1.5), both of which encourage protein synthesis [221]. As discussed
earlier, phosphorylation of 4E-BP1 prevents it binding to eIF4E which enables
eIF4E to bind eIF4G and participate in the formation of the eIF4F initiation
complex along with PABP (Fig.1.8).
When the eIF4F initiation complex is formed it then binds to the m7GTP cap
at the 5’ end of mRNA. This causes circularisation of the mRNA, mediated by
PABP binding to both the poly (A) tail of the mRNA, and eIF4G (Figs.1.7&and
1.8). The eIF4A helicase component of the eIF4F complex then unravels the
mRNA; this activity is enhanced by eIF4B and eIF4H. The 40S small ribosomal
subunit is then recruited to the mRNA by the binding of eIF3 to both eIF4G and
the 43S initiation complex [171].
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1.23 Scanning of the mRNA and localisation of the AUG start codon
After attachment, the 43S complex scans the mRNA downstream of the 5’
cap until it reaches the AUG initiation codon. Although the scanning model of
translation initiation is widely accepted as accurate [222], direct evidence that
this is what happens has still not been demonstrated.
The ‘scanning’ of the mRNA has shown to be directly mediated by the small
eukaryotic initiation factors 1 and 1A, associated with eIF3. These factors have
both been shown to be essential for start codon recognition [223]. Although both
have also been shown to accelerate the formation of the eIF2-GTP-Met-tRNA
ternary complex in vitro, only eIF4A has been shown to stabilise this complex
[224].
Interestingly, the ternary complex associated with eIF1 has also been
observed to be able to carry out ribosomal scanning of unstructured 5’ UTRs
without the need for the eIF4F complex. However, this is only the case for
unstructured mRNAs, as this does not occur when secondary structures are
present [223].
When the start codon is reached, the ribosome halts, binds stably at the
initiation codon (Fig.1.7) and the 40S ribosome undergoes a GTP-mediated
conformational change to stabilise this interaction. The start codon is usually
(but not always) the AUG closest to the mRNA 5’ end and the binding occurs
primarily through the RNA-RNA interaction between the AUG codon and the
CAU anticodon of the bound initiator Met-tRNA.
1.24 60S ribosomal subunit joining
Following the binding of the ribosome to the start codon, the GTPase
activating protein (GAP), eIF5, binds to the  subunit of eIF2 and induces the
hydrolysis of the GTP bound eIF2-Met-tRNA by the  subunit of eIF2. Previous
to this, eIF1 prevents premature hydrolysis of GTP and subsequent release of
eIF2 by stabilisation of the complex. However, during codon-anticodon pairing,
eIF1 is displaced, allowing GTP hydrolysis and eIF2-GDP release [225,226];
eIF2-GDP is then able to be recycled for the next round of initiation.
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Joining of the 60S ribosomal subunit and dissociation of eIF1, eIF1A, eIF3
and residual eIF2-GDP is mediated by eIF5B [227]. eIF5B is a GTPase that
hydrolyses bound GTP, resulting in the release of all previously bound initiation
factors, promoting the binding of the 60S subunit, resulting in the formation of
the 80S ribosome. The GTPase activity of eIF5B is triggered by ribosomal
binding, resulting in the hydrolysis of eIF5B bound GTP, and release of eIF5B-
GDP and eIF1A [228].
1.25 Research aims
The research undertaken during this project aims to select potential chemical
compounds that could downregulate the levels of the MGMT protein so as to be
used in conjunction with TMZ and radiotherapy to increase the efficacy of
anticancer therapies, yet while remaining non-cytotoxic to the cells when used
alone. In addition to this, I also aim to elucidate how the selected compounds
influence cell signalling in both glioblastoma lines that over express the MGMT
protein, and those that are MGMT null.
Chapter II
Materials and methods
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2 Materials and Methods
2.1 Buffers
Lysis Buffer; 20mM MOPS-KOH pH 7.2, 20mM sodium fluoride, 1µM
microcystin LR, 75mM KCl, 2 mM MgCl2, 2mM benzamidine, 2mM Na3VO4,
complete protease inhibitor mix (-EDTA (Roche, UK)), 0.1% (v/v) SDS
Sample buffer; 1.4M β-Mercaptoethanol, 530mM Tris-HCl pH6.8, 0.85% (v/v) 
SDS, 42.5% (v/v) glycerol, 0.05% (w/v) bromophenol blue and 0.05% (w/v)
phenol red
Running buffer; 25mM Tris-HCl pH 8.5, 0.16% (w/v) SDS, 192mM glycine
Anode 1 buffer; 0.3M Tris base pH10, 20% (v/v) methanol
Anode 2 buffer; 25mM Tris base, 20% (v/v) methanol
Cathode buffer; 25mM Tris base, 6-NH2 hexanoic acid, 20% (v/v) methanol
Buffer A; 20mM MOPS-KOH pH 7.2, 75mM KCl, 2mM benzamidine, 7mM
mercaptoethanol, 2mM MgCl2, 0.1mM GTP, complete protease inhibitor mix (-
EDTA), 25mM NaF.
Hypertonic lysis buffer; 150 mM Tris-HCl pH7.5, 10mM KCl, 15mM MgCl2, 1%
(v/v) Igepal, 0.5%(v/v) DOC, 40mM β-glycerophosphate, complete protease 
inhibitor mix (-EDTA), 2mM DTT, 100g/ml cycloheximide, 10 U/ml RNase
inhibitor, 0.1% TritonX-100.
PBS; 137mM NaCl; 2.7mM KCl, 6.5mM Na2HPO4; 1.5mM KH2PO4 , pH 7.3.
TBS-Tween; 50mM Tris-HCl pH7.4, 150mM NaCl, 0.5% (v/v) Tween-20.
ECL developing solution; 0.5mg/ml 5-amino-2,3-dihydro-1,4-phthalazinedione
(luminol) and 11g/ml parahydroxy-coumaric acid in 0.1M Tris-HCl pH 8.6
containing 0.01% (v/v) hydrogen peroxide.
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2.2 Cell Culture
T98G glioblastoma cells (obtained from the ECACC) were cultured to
confluency in minimum essential medium (MEM) supplemented with 5% non
essential amino acids (Invitrogen, UK), 10% foetal calf serum (Biosera, UK) and
5% GlutaMax (Invitrogen, UK). U87-MG glioblastoma cells (obtained from the
ECACC) cells were cultured in the same manner but with Hyclone foetal calf
serum. All cell lines were grown at 37C in humidified atmosphere with 5% CO2.
When treating with chemicals, cells were allowed to grow to 75% confluency
if being treated for 24 hours, or 50% confluency if being treated for 48-72 hours.
2.3 Preparation of cell extracts for Western blotting
To prepare cell extracts, tissue culture dishes of cells were transferred onto
ice and the medium was removed. The cells were scraped into 0.5ml of PBS
and isolated by centrifugation in a microfuge at 15,000 rpm for 1min at 4C. Cell
pellets were then lysed in 200l of Lysis buffer containing 0.5% (v/v) Igepal and
0.5% (v/v) deoxycholate. After thorough vortexing, the cell debris was isolated
by centrifugation at 15,000 rpm for 5 minutes at 4C and the supernatant was
flash-frozen in liquid nitrogen and stored at -80C for further analysis.
2.4 Estimation of protein concentration
Coomassie dye (Bradford reagent) stock solution was diluted 1:4 with distilled
H2O. 1µl of cell lysate was added to 200µl of diluted Bradford reagent. The
colour reaction was quantified by measuring absorbance (A620) minus
background absorbance (A405) using a standard curve of known bovine serum
albumin protein concentrations to calculate the amounts of protein in the
extracts.
2.5 SDS-PAGE and Immunoblotting
SDS-PAGE was used to separate denatured proteins according to their
molecular weight by electrophoresis. SDS-PAGE was performed following the
standard protocol for the mini-gel systems, Protean II or Protean III (Bio-Rad).
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Polyacrylamide resolving gels were composed of 375mM Tris-HCl pH 8.8, 0.2%
(v/v) SDS, 0.1% (w/v) ammonium persulphate (APS), 0.1% (v/v) N,N,N’,N’-
tetramethylethylene diamine (TEMED), and a mixture of acrylamide and bis-
acrylamide in a ratio of 37.5:1. The percentage (w/v) of acrylamide contained in
the resolving gel was varied to suit the molecular weight of the proteins of
interest, ranging from 7.5 to 15%. Stacking gel contained 125mM Tris-HCl pH
6.8, 0.2% (v/v) SDS, 5% (w/v) acrylamide, 0.13% (w/v) bis-acrylamide, 0.1%
(w/v) APS and 0.1% (v/v) TEMED. Samples containing equal amounts of protein
(10µg) were mixed with SDS-PAGE Sample buffer and resolved next to a track
of marker proteins at 100 volts.
Following SDS-PAGE, proteins were transferred to a PVDF membrane (GE
Healthcare, UK) using a semidry transfer apparatus (Semi-Phor, Hoefer, USA).
A ‘sandwich’ composed of 4 sheets of filter paper soaked in Anode1 buffer,
followed by 2 sheets of filter paper soaked in Anode2 buffer, PVDF membrane
wetted in methanol, the polyacrylamide gel, and 4 sheets of filter paper soaked
in Cathode buffer was assembled. The ‘sandwich’ was then placed in the
apparatus and the proteins transferred to the membrane by applying 0.8
mA/cm2 for 2 hours.
After the protein had been transferred to PVDF membrane, non-specific
binding sites of the membrane were blocked by immersion in TBS-Tween with
3% (w/v) bovine serum albumin for at least 30minutes. Afterwards, the
membrane was rinsed three times in TBS-Tween at room temperature, prior to
being incubated in primary antibody (diluted in TBS-Tween with 3% (w/v) bovine
serum albumin) overnight at 4C on a shaker. Next, the membrane was rinsed
and washed three times for 10minutes in TBS-Tween, followed by one-hour
incubation in 2000-fold diluted horseradish peroxidase-conjugated secondary
antibody, and then another three brief rinses and three 10 minute washes in
TBS-Tween. Finally, the membrane was incubated for 1 minute in ECL
Developing Solution, excess solution removed, the membrane wrapped in cling
film and exposed on film for varying length of time according to the intensity of
the signal. The antiserum used were raised against: eIF4A, p-eIF4E, eIF4G,
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eIF4E [229,230]; MGMT, p-eIF2α, (Abcam, UK); total 4E-BP1, p-4E-BP Ser65,
p-4E-BP1 Thr70, p-p70 S6K Thr389, total S6K, α-tubulin, cleaved PARP, p-
AMPKα T172, p- ERK1/2, p-p38 MAPK, p-rpS6 Ser240/44, p-Akt Thr308, p-Akt
Ser473, p21cip1 (Cell signalling, UK). Western blotting experiments presented
are representative of 3 separate experiments unless specified in the figure
legend.
2.6 Cell Treatments
Temozolomide (TMZ), Rapamycin, LY294002, Thalidomide, Spiperone,
Resveratrol, Beta Escin, 4,5-Dianilinophthalimide and AICAR were obtained
from Sigma Aldrich, UK. KU0063794, A769662, Thioridazine and PI-103 were
obtained from Tocris Biosciences, UK. RAD001 was a gift from Novartis, Basel.
Stock solutions were made up in DMSO and mixed thoroughly with tissue
culture media to achieve the required final concentrations.
2.7 [35S]-methionine labelling of cellular protein
One hour prior to harvesting, cells were pulse-labelled with [35S]-methionine
(MP Biomedicals, UK; 10µCi/ml) and cell extracts prepared as above and 5μl of 
extract were then spotted in triplicate onto Whatman filter papers. Filters were
transferred to 10% (v/v) trichloroacetic acid (TCA) containing 5mM unlabelled
methionine for 15 minutes then boiled in 5% (v/v) TCA. Once cooled, the filters
were washed in ethanol, then acetone, dried and subjected to liquid scintillation
counting. Protein synthesis, expressed as cpm/µg protein, is shown as a % of
the rate obtained in cells incubated in the absence of drugs.
2.8 MTS Assay
Metabolism in viable cells produces reducing equivalents such as NADH or
NADPH which pass their electrons to an intermediate electron transfer reagent
that can reduce the tetrazolium product, MTS, into an aqueous, soluble
formazan product. At death, cells rapidly lose the ability to reduce tetrazolium
products. Therefore, the production of a coloured formazan product is
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proportional to the number of viable cells in culture. To measure cell viability,
cells were cultured in a 96 well plate in 100µl of complete medium. Following
incubation in the absence or presence of drugs (see individual figure legends for
details), 20µl of MTS/PMS solution (Promega, UK) was added to each well, and
cells left for 2 hours at 37oC. The colour reaction was quantified by measuring
absorbance at A490 using the control wells for comparison. All assays were
carried out in triplicate.
2.9 RNA extraction and Illumina Microarray analysis
RNA was extracted using Tri reagent and 1-bromo-3-chloropropane (Sigma,
UK). The media was aspirated from each well, and the monolayer of cells
washed once with 1ml of PBS. The PBS was aspirated and 500μl of TRI 
reagent (Sigma, UK) added to each well. The TRI reagent was thoroughly
pipetted to ensure all cells were removed from the plate, and then transferred
into microfuge tubes for storage at -80°C or immediate RNA isolation. If the cells
were frozen, the samples were allowed to defrost for 5 minutes at room
temperature. 100μl of 1-bromo-3-chloropropane (Sigma, UK) was added to each 
sample which was then mixed vigorously for 15 seconds. The samples were
incubated at room temperature for 2 minutes and then centrifuged at 12,000
rpm for 14 minutes at 4°C. The upper aqueous phase was transferred to a new
microfuge tube and mixed thoroughly at a 1:1 ratio with isopropanol (Fisher
Scientific, UK). The samples were incubated at room temperature for 10
minutes and centrifuged at 12,000 rpm for 10 minutes at 4°C.
The supernatant was discarded, and the pellet washed twice with 75% ice-
cold ethanol (75% absolute ethanol, Fisher Scientific, UK, 25% molecular
biology grade water, VWR, UK), then centrifuged at 12,000 rpm for 5 minutes at
4°C. The supernatant was discarded, and the last traces of ethanol removed
with gel-loading pipette tips. The RNA pellet was dried in a Savant DNA Speed-
Vac for 2 minutes and resuspended in 25μl of molecular biology grade water. 
The RNA concentration was measured by 260/280 nm absorbance ratio on a
Nanodrop spectrophotometer.
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RNA integrity was then measured by microfluidics analysis using the Agilent
2100 bioanalyzer and RNA Nano 6000 kit (Agilent Technologies, UK) according
to the manufacturer’s instructions. Briefly, 1µl of sample containing 50-500ng of
RNA was pipetted into a chip containing glass micro-channels filled with a gel
containing RNA intercalating fluorescent dye. A current was applied to the gel,
separating the RNA molecules by size. The RNA was detected by fluorescence
and used to construct gel-like images. RNA quality was assessed by the relative
widths of the 18S and 28S ribosomal bands, and expressed as an RNA Integrity
Number (RIN) [231]. A RIN of between 8 and 10 indicates RNA integrity
sufficient for microarray analysis.
Genome-wide gene expression analysis was carried out using the Illumina
Microarray platform. Illumina microarrays are single-channel microarrays with
50mer oligonucleotide probes attached to beads mounted to a mirrored glass
slide.
RNA obtained from MCF7 cells treated with 10µM KU0063794 for 6 hours,
cells treated with 20µM A769662 for 6 hours and untreated control cells was
converted to biotinylated cRNA using an Illumina TotalPrep RNA amplification
kit (Ambion, UK). The cRNA was prepared according to the manufacturer’s
instructions. 500ng of RNA was reverse transcribed to cDNA using a master mix
containing oligo (dT) primer, buffer, dNTP mix, RNase inhibitor and ArrayScript
(reverse transcriptase) and incubated for 2 hours at 42°C.
Second strand cDNA synthesis was performed by adding a master mix made
up of nuclease-free water, buffer, dNTP mix, DNA polymerase and RNase H.
The sample was then incubated for 2 hours at 16°C. The cDNA was purified
using cDNA filter cartridges and several centrifugation and wash steps, before
being eluted in nuclease-free water. The purified cDNA was transcribed to
biotinylated cRNA by adding a master mix of buffer, T7 enzyme mix (RNA
polymerase), and a biotin-NTP mix and incubated at 37°C for 14 hours. The
biotinylated cRNA was purified using cRNA filter cartridges and several
centrifugation and wash steps, before being eluted in nuclease-free water. The
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integrity of the resulting cRNA was measured by microfluidics analysis using the
Agilent 2100 bioanalyzer and RNA Nano 6000 kit as outlined above.
Microarray hybridization was carried according to Illumina manufacturer’s
instructions. Briefly, 750ng of cRNA was prepared in a volume of 5μl of 
nuclease free water. The cRNA was mixed with 10µl of hybridization buffer, and
denatured at 65°C for 5 minutes. The cRNA samples for MCF7 cells exposed to
estradiol were then injected onto Illumina HT-12 v3 Expression BeadChips
(Illumina, USA). The cRNA was hybridized to the BeadChips in a humidified
hybridization chamber over an 18 hour incubation period at 58°C.
The Illumina BeadChips were washed and scanned according to the
manufacturer’s instructions. The BeadChip was blocked using a block buffer,
and stained with cy3-labelled streptavidin. This was followed by several more
wash steps, before the BeadChip was dried by centrifugation at 275 g for 4
minutes. The BeadChip was immediately loaded into an Illumina BeadArray
Reader and scanned at a wavelength 532 nm using a laser at default power and
PMT parameters.
2.10 Microarray data analysis and connectivity mapping
Raw probe expression values are stored in .IDAT files. The .IDAT files were
imported into GenomeStudio Data Analysis Software. During the import
process, fluorescence values for repeated probes were combined to produce
one mean fluorescence value per probe. The data was then exported in .txt file
format. Microarray data was normalized, stored and handled using ArrayTrack
software [232] and a storage account kindly set up by ArrayTrack on their
server. Illumina microarray data, in .txt file format, was imported into ArrayTrack
and normalised using a quantile normalisation algorithm. Control and treated
normalised microarray datasets were compared using a Welch t-test.
Differentially expressed genes were filtered by p value (<0.05).
In order to query the original connectivity map, microarray data must be in the
same naming format as the connectivity map database - Affymetrix (HT)
HGU113A probe identifiers. Therefore, in-house generated Illumina microarray
34
data had to be converted to Affymetrix probe identifiers. Illumina probe
identifiers were converted to HUGO gene names using ArrayTrack software
loaded with Illumina annotation files. Microarray data in HUGO gene naming
format was exported from ArrayTrack in .txt file format. The .txt files were
imported into a Microsoft Access database loaded with an Affymetrix annotation
file, and a query set up to match the HUGO gene names of the microarray
dataset with the annotation file. The microarray dataset was assigned Affymetrix
probe identifiers. Where several Affymetrix probes represented a gene, all the
Affymetrix probes were included, and the file exported in .txt format.
The most differentially expressed genes were selected as gene signatures to
query the connectivity map. These were selected primarily by highest absolute
log2 fold change. Where possible, p value (<0.05) was used to filter out genes
with a higher sample variation. In some cases with Affymetrix data, where
background fluorescence can be a problem, filtering out differentially expressed
genes with low mean channel intensities was employed. Connectivity mapping
was carried out using the sscMap connectivity mapping program with either the
standard connectivity map database (in Affymetrix probe identifier format) or the
HUGO connectivity map database (in HUGO gene name identifier format).
A product of converting a non-Affymetrix microarray dataset to Affymetrix
format is that it necessitates the inclusion of all the Affymetrix probes
representing a gene. The impact that this has on connectivity mapping accuracy
was modelled using an Affymetrix dataset for MCF7 cells exposed to 10nM
estradiol for 6 hours in charcoal-stripped serum conditions. The 30 most
changed genes were selected by highest absolute log2 fold change and used as
a gene signature to query the connectivity map. This was repeated using the
same gene signature with all of the probes representing each gene included.
The 6100 microarray datasets which make up the connectivity map database
were converted from Affymetrix probe identifier format to HUGO gene name
format. To achieve this, a VBA macro was designed to automate the process.
The connectivity map algorithm cannot deal with duplicated gene names. Where
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several gene names were present only the gene with the highest absolute log2
fold change was maintained, the others were removed
2.11 Fluorescence activated cell sorting
Following incubation of cells as described in the figure legends, cells were
washed with warm PBS then trypsinised and removed from culture dishes. Cells
were washed in PBS and fixed in 70% ethanol/30% PBS at 4ºC overnight.
Immediately before analysis, the cells were washed in PBS and resuspended in
500µl PBS containing 0.1mg/ml RNase A (Sigma, UK) and 30µg/ml propidium
iodide (Invitrogen, UK) and analysed by a FACSCantoTM flow cytometer (BD
Biosciences) using BD FACSDivaTM software. Data shown are representative of
those obtained in at least three separate experiments.
2.12 Quantitative real–time RT-PCR
RNA was extracted from cell extracts using an RNA easy mini-kit (Qiagen,
UK) as per manufacturer’s instructions. RNA concentrations were then
quantified using a Nanodrop and 1µg of RNA was used for cDNA synthesis
using the Promega ImpromII kit. The SYBR real-time PCR system (Kapa
Biosystems, UK) was used to quantify transcript abundance for genes of interest
and 18S mRNA was used as a control. Template equivalent to 5ng of RNA in
cDNA library per reaction was added to each 20μl reaction with a final primer 
concentration of 200nM per reaction. Crossing thresholds were determined
using MxPro software (Agilent), and fold-difference in RNA quantity was
calculated using the relative quantification method (2-ΔΔct).
Dissociation curves for both 18S primers and MGMT primers were calculated
to ensure amplicons were the correct length, and therefore the primers were
binding specifically.
2.13 Immunofluorescence analysis of MGMT in T98G cells
Cells were plated on glass coverslips 8 hours before treatment. Cells were
then fixed with 4% (w/v) paraformaldehyde for 20 minutes at room temperature
Figure 2.1 Dissociation curve of 18S amplicons
The dissociation curve shows the melting temperature of the RNA strands amplified by the 
specific primers. 
Figure 2.2 Dissociation curve of MGMT amplicons
The dissociation curve shows the melting temperature of the RNA strands amplified by the 
specific primers. 
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and permeabilised for 5 minutes in 0.1% (v/v) Triton X-100/PBS. Cells were
blocked for 20 minutes with 5% (w/v) gelatin/PBS in a humidified chamber. Cells
were incubated with anti-MGMT (Abcam, UK) for 1 hour at room temperature
also in a humidified chamber. Alexa Fluor 555-conjugated anti-rabbit secondary
antibody was added for 1 hour at room temperature. Alexa Fluor 488 phalloidin
was also used in the secondary antibody incubation. Following further extensive
washing, nuclei were stained with DAPI (4’, 6-diamidino-2-phenylindole) for
5 minutes. After a further two washes, coverslips were mounted on microscope
slides with Mowiol mounting solution (0.2 M Tris-HCl pH 8.5, 33% (w/v) glycerol,
13% (w/v) Mowiol and 2.5% (w/v) DABCO (1, 4-diazobicyol [2, 2, 2]-octane))
and sealed with clear nail polish. Images were collected on a Zeiss Axiovert
LSM510 scanning confocal microscope using a ×100 objective. Single stain,
bleed-though controls and antibody cross-reaction controls were prepared for
each sample.
2.14 Optical Microscopy
Cells were grown in 5cm plates then visualised with a Nikon eclipse t5100
microscope. Images were collected using a Moticam 2000 2 megapixel mounted
camera.
2.15 M7GTP sepharose affinity chromatography
To isolate eIF4E and associated proteins [229,230], cells were lysed as
described and aliquots containing 100µg were incubated with 30µl m7GTP-
Sepharose resin (50% v/v in 1mg/ml cytochrome c) for 15 minutes on ice, with
mixing. The resin was washed twice in 200µl Buffer A then eluted in SDS-PAGE
sample buffer containing 10% w/v β-mercaptoethanol, prior to Western blotting.  
2.16 Polysome profiles
Cells were treated with 10µg/ml of cycloheximide (Sigma, UK) for 3 minutes
before harvesting. The cells were then washed twice in PBS containing 10µg/ml
cycloheximide and lysed in Hypertonic lysis buffer for 10 minutes at room
Figure 2.3 A schematic representation of the M7GTP sepharose beads actively 
bound to initiation factors
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temperature, then a further 20 minutes on ice. The cell lysate was centrifuged at
14,000rpm for 3 minutes and the supernatant was separated on a 7.6ml sucrose
gradient (10-60% (w/v) in hypertonic lysis buffer) for 130 minutes at 38,000 rpm
using a Beckman SW40 rotor. Optical density profiles and gradient fractions
were obtained by upward displacement of the sucrose gradients with pumping
sucrose (60% (w/v) sucrose) through an ISCO UA6 gradient fractionation
machine coupled to a UA5 spectrophotometer measuring the absorbance at
254nm.
The RNA was precipitated from each fraction by adding 150l 2M NaCl, 10g
Glycogen and 1ml of filtered Isopropanol. The tubes were then vortexed until
thoroughly mixed and left at room temperature for 20 minutes to initiate the
precipitation, before being frozen at -20ºC. The samples were then thawed
before being centrifuged at 14,000rpm for 45 minutes at 10ºC. The samples
were then washed twice in 1ml of cold ethanol and centrifuged at 14,000rpm
and 4ºC to remove the salt. The supernatant was removed and the pellets left to
dry in the fume hood. The pellets were resuspended in 100l of Ambion
Lysis/Binding buffer, left for 5 minutes and then 100l of Phenol (Ambion) was
added. The samples were then centrifuged at room temperature and 10,000rpm
for 10 minutes and then the upper phase was removed and placed in a clean
cold microfuge tube. The RNA was then purified according to the NucleoSpin
RNA II isolation kit (Macherey-Nagel) and qRT-PCR was carried out as
described above.
2.17 eIF4A helicase reporter assays
To assay eIF4A activity in cells, assays were carried out by Dr. Thomas
Webb (University of Nottingham), using the technique outlined in [233]. Briefly,
SH-SY5Y cells were co-transfected in triplicate with pGL3-(6x) HRE–firefly
luciferase and TK–Renilla luciferase reporters. The cells were then incubated
overnight with chemicals and concentrations specified in the corresponding
figure legends. 24 hours post-transfection, cells were freeze–thawed and lysed
in 1× passive lysis buffer (Promega). The cell samples were assayed for
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luciferase activity using LarII and Stop and Glo reagents (Promega) and a
GloMax luminometer (Perkin Elmer).
Chapter III
Identifying potential therapeutic candidates 
using patient material: Connectivity mapping
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3 Identifying potential therapeutic candidates using patient material:
Connectivity mapping
3.1 Aims
 To identify compounds that will decrease MGMT protein levels
 To use connectivity mapping with patient data to identify these
compounds
 To ensure the compounds are not cytotoxic to cells
3.2 Introduction
3.2.1 Connectivity mapping: an overview
Connectivity mapping is a technique that combines a reference collection of
gene expression profiles derived from cultured human MCF7 breast cancer cells
treated with bioactive small molecules, with an algorithm that searches for
similarities or differences between these profiles. The technique is based upon
the principle that a transcription pattern can be used as a fingerprint to describe
a chemical-induced biological condition. By identifying similarities between the
transcription patterns produced by different chemicals, functional similarities or
“connections” can be identified between those compounds. Connectivity
mapping was originally designed and implemented by Lamb et al. in 2006 [234].
The technique was then refined by Zhang et al. in 2009. I have implemented this
refined technique as it normalises the data, making the analysis less error prone
than the original format.
There are three main stages to connectivity mapping (Fig.3.1). Firstly, there is
a reference database that contains gene profiles of MCF7 breast cancer cell
lines. The gene profiles are generated by treating the cells with a known
concentration of a compound for 6 hours. A genome-wide mRNA microarray is
then performed on both the treated cells, and an untreated control. The changes
in mRNA expression between the two samples are then quantified, and a list
compiled of the top 30 or top 100 most changed genes (whichever describes the
changes best). The list is arranged in descending order, with the most changed
Figure 3.1 Flow diagram representing the stages of connectivity mapping
This flow diagram outlines the main stages of connectivity mapping. First MCF7 cells are treated 
for 6 hours with a compound. A microarray is then performed on these cells and an untreated 
control. The treated and untreated samples are then compared and the top 30 or 100 (depend-
ing on which is most descriptive of the gene change) are selected. The most changed genes 
list then represents this compound. The connectivity map database is made up of thousands of 
compounds that have been processed in this fashion. The connectivity map can then be queried 
to find chemicals that produce a similar (or dissimilar) expression pattern. 
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genes at the top (“most changed” gene expression includes both up-regulated
and down-regulated genes).
The second stage of connectivity mapping involves either creating a query
gene signature by doing an “in house” microarray on cells treated with a
compound of interest, or obtaining microarray data from the original database
created by Lamb et al. [234]. For the approach to be successful, the query gene
signature has to accurately define the biological state change compared to the
control, whilst being shorter than the genome-wide list of genes. The query gene
signature, therefore, is simply a list of genes whose expression changed as a
result of a disease state or induced by treatment with a compound (compared to
a control). This list is then ranked in descending order, with the genes which had
the highest fold change in gene expression at the top.
The third and final stage of the connectivity mapping procedure is the use of
an algorithm that determines similarities between the query gene signature, and
the reference gene signatures in the database. The connection strength of a
query signature to a reference signature is determined by multiplying the values
assigned to genes (the fold change in gene expression) in the query signature
with the values assigned to genes in the reference database (Fig.3.2).
Figure 3.2 The sscMap scoring scheme
The sscMap algorithm scoring scheme involves the multiplication of values
associated with genes contained in the gene signature, with the values associated with
the corresponding genes in each reference profile. Where C is the connection strength;
R is a reference profile; s is a gene signature; n is the number of genes in a gene
signature, gi is a gene in the gene signature and R(gi) and s(gi) are the gene ranks in
the reference profile and gene signature respectively [235].
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The connection strength can then be used to generate a connection score,
which is calculated by dividing the connection strength by the maximum
possible connection strength (Fig.3.2).
c = C (R, s)/Cmax(N, n)
Figure 3.3 Connection score calculation
The connection score is calculated by dividing the connection strength by the
maximum possible connection strength. Where c is the connectivity score; C is the
connection strength; R is a reference profile; s is a gene signature; N is the total
number of genes in the reference profile and n is the number of genes in a gene
signature [235].
The connection score calculated by these formulae can be a positive or a
negative value. A positive score indicates similarities between the gene changes
in the reference profile data and the query profile data. Alternatively, a negative
connection score indicates an inverse transcriptional change between the gene
signature and reference profile. In order to establish a measurement of
statistical significance, the connection strength for a particular gene signature is
compared with the connection strength of 10000 random gene signatures of the
same length.
3.2.2 Connectivity mapping: applications
Connectivity mapping has a wide range of applications, yet being a relatively
new technique, not all of these applications have been explored thoroughly.
Connectivity mapping has been most commonly implemented to find novel
chemical functions by identifying similarities between compounds effects on
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gene expression. Examples of this include the identification of a transcription
pattern induced by a specific HSP90 inhibitor and the subsequent identification
of novel HSP90 inhibitors (celastrol and gedunin) [236] and the detection of
novel inhibitors of HIF2α activity using transcription patterns for the HIF2α-
inhibitor PGJ2 [237]. The use of connectivity mapping to detect novel chemical
function based on a transcription pattern for a pathological process has also
been tested. A transcriptional profile for glucocorticoid resistance identified the
mTORC1 inhibitor rapamycin as a novel glucocorticoid sensitising agent [238].
These examples suggest many new and exciting applications for connectivity
mapping, especially in aiding the discovery of novel chemical functions of
chemicals that may otherwise have been discarded as ineffective for their
intended use. Here I will use both disease states and chemical compounds to
identify new and exciting chemical functions that could have therapeutic effect
on MGMT protein levels in GBM cells.
3.3 Results
3.3.1 Connectivity mapping using patient material
Initially, microarray data was obtained from Lambiv et al. [239] from patients
with temozolomide and radiotherapy-resistant GBM. The data was derived by
comparing the gene changes shown in microarray profiles between samples of
GBM that were unresponsive to treatment, compared to those that were
responsive to therapy. The gene changes used to define the TMZ resistant
GBM samples are listed in Table 3.1.
These sample data underwent connectivity mapping analysis, and the
negatively scored results (therefore chemicals that created a gene signature
inverse to that of the disease state and the resistance) are listed in Table 3.2.
Interestingly the majority of compounds were antipsychotics, but positive
connections were also produced by PI3K inhibitors, RTK inhibitors and
angiogenesis inhibitors.
Table 3.1 Top 30 most changed genes in TMZ resistant GBM patient samples
The top 96 genes in TMZ resistant GBM samples that had the highest fold change compared 
to a non-resistant GBM control were used to define the query gene signature, of these, the 
top 30 are displayed. 
Gene name Fold change
RTP4 1.134483822
CHST8 -1.110915901
CD55 -1.104076998
CA10 -1.089574327
ISG15 0.968717474
IFI44L 0.957023083
PCP4 0.939377047
CLIC2 -0.932085986
ANXA3 -0.914031546
IL20RA 0.90126274
MX1 0.900567372
RSAD2 0.888226952
NF2 0.877979773
CCRL1 0.87530826
IFIH1 0.791689067
LRRC48 0.790021308
PTGER3 0.767570056
WDR78 0.756510956
HIGD2A -0.711228033
HAP1 -0.710755715
MECP2 0.673013615
IFIT3 0.659924558
SELENBP1 0.649385529
STAT1 0.630125852
CYP39A1 0.627886946
EIF1 0.620492574
CHEK1 0.6098495
PDE3B 0.58168868
IGF1R -0.57949065
Table 3.2 Candidate drugs suggested to reverse the gene changes brought about by 
 Temozolomide resistance in human samples
The cMap build 2 database was searched for negative connections to a gene signature 
derived from patient samples of TMZ resistant GBM. The top 96 genes that had the high-
est fold change compared to a non-resistant GBM control were used to define the query 
gene signature. The database contained 3738 sets of reference profiles and the expected 
number of false connections to tolerate was 1. The threshold p value was therefore set at 
2.675227394328518e-4 (1/3738) and any connection with a p value lower than this declared 
significant. All chemicals shown in the table are deemed significant. The top 40 candidate 
drugs are shown. 
Reference set name Reference set score
triamterene -4.89966926
dequalinium chloride -4.875095613
spiperone -4.667354237
digoxin -4.412556603
methylbenzethonium chloride -4.369968855
butoconazole -4.338523302
altretamine -4.261400367
mitoxantrone 4.110896614
tonzonium bromide -4.100504909
proscillaridin -4.091748982
antimycin A -4.072536566
lanatoside C -4.055869411
pyrvinium -4.051160489
NU-1025 -4.030434451
ouabain -4.010658905
pipenzolate bromide -3.976884464
alexidine -3.974620998
flumetasone -3.974353309
sulfadiazine -3.966747222
thioridazine -3.926260218
octopamine -3.902298628
tiabendazole -3.878739069
beta-escin -3.870456348
colchicine -3.851894778
Prestwick-682 3.84700215
oxedrine 3.820716804
terfenadine -3.80995331
metrifonate -3.807393122
cicloheximide -3.806058845
ciclacillin -3.786550231
LY-294002 -3.785180231
thalidomide -3.741528782
lycorine -3.738504899
buspirone -3.71854776
triflupromazine -3.686221853
felodipine -3.627822445
R-atenolol -3.59555864
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3.3.2 Initial treatment of T98G cells with rapamycin, LY294002, PI103 and
Torin 1
Mutations in the mTOR signalling pathway is commonly seen in GBM cells
can result in hyperactive PI3K/ERK/mTOR signalling, promoting cell survival
and protein synthesis [75,142,240]. The hyperactivity of these signalling
pathways allows cancerous cells to grow quickly and to effectively resynthesise
proteins. One particular protein whose constant synthesis has the potential to
cause problems during chemotherapeutic treatment with TMZ is the DNA repair
protein, MGMT. MGMT is a “suicide” repair protein that binds irreversibly to a
DNA adduct (such as those caused by TMZ) and is destroyed by the
proteasome once repair has taken place (Fig.1.3). Therefore, the ability of the
cell to resynthesise MGMT and repair DNA damage could be the basis for TMZ
resistance in GBM cells.
With this in mind, the initial inhibitors that were screened for potentially
reducing MGMT protein levels in GBM cells included the PI3K inhibitor
LY294002 which was identified by connectivity mapping of the TMZ-resistant
GBM patient samples. Other compounds were chosen because they were also
PI3K inhibitors, or affected proteins directly upstream or downstream of
PI3K.This included the mTORC1 inhibitor rapamycin, the PI3K inhibitor PI103
and the dual mTOR inhibitor Torin 1.
During the compound treatments T98G cells were treated with four different
final concentrations of each inhibitor for 24 hours. Before compound treatments
commenced, I ensured that complete cell lysis was being achieved from the
T98G cells by using Lysis buffer containing differing concentrations of SDS
detergent. I wanted to ensure that all of the MGMT was being extracted from the
cells, as it is possible that if a protein is associated with an intracellular
component, such as the ER, and cell lysis is incomplete, the proteins can be
separated from the lysate during the centrifugation step of protein extraction and
discarded. However, the lysis of the cell in the presence of SDS confirmed this
was not occurring.
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Western blotting was then used with anti-serum against eIF4A and MGMT
to visualise protein levels (Fig.3.4). The eIF4A loading control showed that 0.1-
0.2% SDS was optimal for protein recovery in this experiment. MGMT protein is
present in both the cytoplasm and the nucleus and the data shown in Figure 3.4
suggests that at least 0.1% SDS is optimal for MGMT protein recovered from
the cells. Increasing detergent concentrations does not have a huge impact on
MGMT protein recovery in these cells. I therefore continued to use 0.1% SDS in
the Lysis buffer throughout my experiments to ensure whole cell lysis.
In addition to western blotting analysis, possible cytotoxicity of these
compounds was also measured using an MTS assay and the morphology of the
cells was assessed under the microscope. A drawback of the MTS assay is that
lower readings from the cells as a result of increased mitochondrial toxicity
could be disguised by an increase in cell number in the well; this is why I also
observed the cells growth and morphology under a light microscope.
3.3.3 Rapamycin treatment leads to increased steady state levels of
MGMT in T98G cells
Rapamycin is a macrolide antibiotic, produced by Streptomyces
hygroscopicus which inhibits mTORC1 activity by forming a complex with FKBP-
12 and binding to mTOR [72]. The data presented in Figure 3.5 shows that in
T98G cells, complete inhibition of mTORC1 with rapamycin is only complete at
the high concentrations. This is suggested by the fact that rapamycin does not
lead to the complete dephosphorylation of 4E-BP1 (Fig.3.5 A, lanes 1-5).
However, this could also be a result of the speed at which 4E-BP1 becomes
dephosphorylated after mTORC1 inhibition. Surprisingly, even though the
recovery of eIF4A was constant between treatments, MGMT protein levels were
seen to increase as the concentration of rapamycin increases. In addition the
level of phosphorylated-eIF2 was also shown to increase with increasing
concentrations of rapamycin (lanes 3-5), suggesting that the cells are
undergoing an alternative form of stress [241]. Rapamycin is not cytotoxic at any
of the concentrations used (Fig.3.5B) but Figure 3.5C shows that, relative to
eIF4A
MGMT
0 0.1 0.2 0.4 % SDS
1 2 3 4
Figure 3.4 Effects of SDS on the recovery of MGMT
T98G cells were grown for 24 hours in complete medium. Cells were harvested and sam-
ples were lysed in the absence (lane 1) or presence of differing percentage concentrations 
of SDS (lanes 2,3 and 4). Aliquots containing 10mg of protein were resolved by SDS-
PAGE and proteins visualised by Western blotting using the antiserum indicated (n=1).
AFigure 3.5 High concentrations of rapamycin prevent 4EBP1 phosphorylation without  
 promoting cell death
Panel A. T98G cells were incubated for 24 hours in the absence (lane 1) or presence of differ-
ing concentrations of rapamycin (lanes 2-5). Extracts were prepared and aliquots containing 
10mg of protein were resolved by SDS-PAGE and proteins visualised by Western blotting using 
the antiserum indicated (n=2) Panel B. T98G cells were treated as in (A) and cell viability was 
assessed using an MTS assay as described in Materials and Methods. Results are expressed 
relative to those obtained in untreated cells (set at 100%). Error bars are the S.D (n=3). Panel 
C. T98G cells were incubated for 24 hours in the absence or presence of 10 mM rapamycin. 
Cells were subjected to light microscopy using a Nikon eclipse T5100 and images captured 
with a Moticam 2000 camera.
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untreated cells; incubation of cells with 10M rapamycin inhibits cell growth over
24 hours.
3.3.4 LY294002 did not reduce MGMT levels in T98G cells
LY294002 is a highly selective PI3K inhibitor which also has the ability to
directly inhibit mTOR when used at high concentrations [242]. To investigate the
effect of LY294002 on steady state levels of MGMT, T98G cells were incubated
with different concentrations of LY294002 for 24 hours. Figure 3.6A (lane 4 vs.
lanes 1-3) shows that at concentrations above 10M, there was a
dephosphorylation of 4E-BP1, characteristic of an inhibition of mTOR signalling.
Alongside this, MGMT protein levels were maintained up to levels of 10M
LY294002 (lane 2-4 vs. lane 1), then decrease with 50M of LY294002 (lane 5
vs. lanes 2-4). As with cells incubated with rapamycin (Fig.3.5), the
phosphorylation of eIF2 was also seen to increase in cells incubated with
LY294002 (lanes 2-4 vs. lane 1). An MTS assay showed no increase in
mitochondrial toxicity following incubation of cells with LY294002 (Fig.3.6B) but
light microscopy (Fig.3.6C) shows that LY294002 inhibits cell proliferation.
3.3.5 PI103 does not increase steady state levels of MGMT and promotes
apoptosis
PI103 is a kinase inhibitor that has been suggested to inhibit PI3K, mTOR
and DNAPK [243,244]. In T98G cells treated with PI103 for 24 hours, only a
high concentration of drug showed an inhibition of mTOR signalling, as
characterised by dephosphorylation of 4E-BP1 (Fig.3.7, lane 5 vs. lanes 1). In
contrast to rapamycin, there was no general increase in levels of MGMT with
increasing drug concentrations. An MTS mitochondrial toxicity assay (Fig.3.7B)
showed no significant inhibition of mitochondrial function with increasing
concentrations of PI103 over 24 hours. However, analysis of cells by light
microscopy suggests that high concentrations of PI103 inhibit cell growth;
furthermore, blebbing can be seen in these cells suggesting that they are
beginning to enter apoptosis (Fig.3.7C).
AFigure 3.6 LY294002 inhibits mTOR signalling when used at high concentrations
Panel A. T98G cells were incubated for 24 hours in the absence (lane 1) or presence of differ-
ing concentrations of LY294002 (lanes 2-5). Extracts were prepared and aliquots containing 
10 mg of protein were resolved by SDS-PAGE and proteins visualised by Western blotting us-
ing the antiserum indicated. (n=2) Panel B. T98G cells were treated as in (A) and cell viabil-
ity was assessed using an MTS assay as described in Materials and Methods. Results are 
expressed relative to those obtained in untreated cells (set at 100%). Error bars are the S.D 
(n=3). Panel C. T98G cells were incubated for 24 hours in the absence or presence of 10 mM 
LY294002. Cells were subjected to light microscopy using a Nikon eclipse T5100 and images 
captured with a Moticam 2000 camera. 
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AFigure 3.7 PI103 inhibits mTOR signalling at high concentrations but is cytotoxic
Panel A. T98G cells were incubated for 24 hours in the absence (lane 1) or presence of dif-
fering concentrations of PI103 (lanes 2-5). Extracts were prepared and aliquots containing 10 
mg of protein were resolved by SDS-PAGE and proteins visualised by Western blotting using 
the antiserum indicated (n=1) Panel B. T98G cells were treated as in (A) and cell viability 
was assessed using an MTS assay as described in Materials and Methods. Results are 
expressed relative to those obtained in untreated cells (set at 100%). Error bars are the S.D 
(n=3). Panel C. T98G cells were incubated for 24 hours in the absence or presence of 100 
mM PI103. Cells were subjected to light microscopy using a Nikon eclipse T5100 and images 
captured with a Moticam 2000 camera.
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3.3.6 Torin 1 is an effective mTORC1/2 inhibitor in T98G cells
Torin 1 is a selective dual mTORC1/2 inhibitor which targets the active site of
the mTOR kinase [245]. Over a 24 hour incubation period in T98G cells, at low
concentrations, Torin 1 results in the dephosphorylation of 4E-BP1 (Fig.3.8,
lanes 2-5 vs. Lane 1), indicating that incubation with the compound results in an
inhibition of mTOR signalling. However, in contrast to rapamycin (Fig.3.5A) and
LY294002 (Fig.3.6A), incubation of cells with Torin 1 did not result in an
increase in steady state levels of MGMT, and actually showed a reduction in
MGMT when treated with 0.5µM for 24 hours (Fig.3.8A). A cell viability assay
using MTS alongside light microscopy showed a slight increase in mitochondrial
toxicity in cells treated with Torin 1 compared to an untreated control and a
moderate inhibition of cell proliferation (Figs. 3.8B and 3.8C, respectively).
3.3.7 The effect of rapamycin, LY294002, PI103 and Torin 1 on protein
synthesis rates in T98G cells
The initial drugs tested here were either identified directly, or were closely
related to those that were identified by connectivity mapping of TMZ resistant
GBM samples. However, they had different effects on the steady state level of
MGMT protein and mTOR signalling over a 24 hour incubation period with
varying concentrations of the compounds. Therefore, in an attempt to correlate
MGMT protein levels, mTOR signalling and translation, in parallel I measured
the effect of these compounds on cell viability (Fig.3.9A) and the rate of protein
synthesis (Fig.3.9B). I also investigated the effect of TMZ on protein synthesis
rates under these assay conditions. At the concentrations of compounds used
here, there was no significant decrease in cell viability under any condition
(Fig.3.9A). In contrast, effects of the rate of protein synthesis varied
dramatically. As shown in Figure 3.9B, treatment of cells with PI103 or TMZ had
a moderate effect on protein synthesis rates. High concentrations of rapamycin
resulted in a reduction in [35S] methionine incorporation into protein but resulted
in an increase in the steady state levels of MGMT. This is discussed in more
AFigure 3.8 Torin 1 inhibits mTOR signalling and reduces MGMT levels
Panel A. T98G cells were incubated for 24 hours in the absence (lane 1) or presence of differ-
ing concentrations of Torin1 (lanes 2-5). Extracts were prepared and aliquots containing 10mg 
of protein were resolved by SDS-PAGE and proteins visualised by Western blotting using the 
antiserum indicated (n=2) Panel B. T98G cells were treated as in (A) and cell viability was 
assessed using an MTS assay as described in Materials and Methods. Results are expressed 
relative to those obtained in untreated cells (set at 100%). Error bars are the S.D (n=3). Panel 
C. T98G cells were incubated for 24 hours in the absence or presence of 0.5 mM Torin1. Cells 
were subjected to light microscopy using a Nikon eclipse T5100 and images captured with a 
Moticam 2000 camera.
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AFigure 3.9 Effects of compounds on mitochondrial function and protein synthesis
Panel A. T98G cells were treated with the final concentrations of the drugs and incubated 
for 24 hours. Cell viability was assessed using an MTS assay as described in Materials and 
Methods. Results are expressed relative to those obtained in untreated cells (set at 100%). 
Error bars are the S.D (n=3). Panel B. T98G cells were treated as in (A) and one hour prior 
to harvesting, cells were incubated with 10µCi/ml [35S] methionine, as described in Materials 
and Methods. Cells were harvested, extracts were prepared and incorporation of radioactive 
methionine into protein determined as cpm/mg protein; results are presented as a % of the rate 
obtained in cells incubated in the absence of drugs. Error bars are the S.D (n=3). A standard T 
Test was performed and p values were assigned limits where * <0.05, **<0.005, ***<0.001. 
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detail later in the thesis. However, as previous studies showed little effect on
4E-BP1 phosphorylation status (Fig.3.5A) and could reflect the phosphorylation
of eIF2.
Incubation of cells with LY294002 promoted a dephosphorylation of 4E-BP1
and a severe inhibition of protein synthesis rates; however, it did not reduce
MGMT protein levels at most concentrations and was therefore not carried
forward in this study. The mTOR inhibitor, Torin 1, did show some promising
results, with low toxicity and mTOR inhibition. However, due to availability
issues, it was replaced with commercially available, KU0063794, which is a very
similar dual mTORC1/2 inhibitor.
3.4 Summary
 Torin 1 was the only compound screened that reduced MGMT protein
levels over a 24 hour treatment.
 LY294002 was the only compound screened that was directly
identified using connectivity mapping and it did not reduce MGMT
protein levels over 24 hours.
 None of the compounds screened were cytotoxic at low levels.
3.5 Conclusions
The initial experiments carried out to screen compounds abilities to reduce
MGMT levels in T98G cells produced some interesting findings. Firstly,
rapamycin treatment of cells was shown to increase MGMT protein levels in a
dose dependent manner, yet while reducing protein synthesismost probably
through inhibition of cap dependent translation. Secondly, although LY294002
did not reduce MGMT protein levels when used alone, it did reduce protein
synthesis rates, and did not increase levels of MGMT protein, making it a
possible therapeutic candidate for using in addition to another compound.
Thirdly, a dual mTOR inhibitor, Torin 1, did reduce levels of MGMT protein at
certain concentrations, making it an attractive compound for further research.
Chapter IV
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4 Using custom gene signatures and chemical compounds to identify
mTOR signalling inhibitors
4.1 Aims
 To identify compounds that will reduce MGMT protein levels
 To use connectivity mapping with known compounds and custom gene
signatures to identify these compounds
 To ensure the compounds are not cytotoxic to cells
4.2 Introduction
During the previous chapter I showed that rapamycin and LY294002 both
reduced protein synthesis rates in T98G glioblastoma cells. I also showed that a
dual mTOR inhibitor reduced levels of MGMT protein in T98G cells. Because of
this, I used connectivity mapping to mine for compounds that are known to
inhibit PI3K and mTOR, whilst avoiding the possible cytotoxicity faced if multiple
compounds were administered concomitantly.
In addition to the connectivity mapping experiments that were used to identify
compounds that gave similar outputs to LY294002, rapamycin and the custom
gene list, I also wanted to search for other possible direct dual mTORC1/2
inhibitors, and explore if any of the compounds found in the previous searches
were produced in response to an mTORC1/2 inhibitor query. Furthermore, as
many of the compounds produced in the connectivity mapping were AMPK
activators (which generally cause little cytotoxicity); I also wanted to query the
database for compounds that showed positive connections to other AMPK
activators.
It was important at this stage to discontinue using drugs that were cytotoxic to
the cells when used alone, as the purpose of the chosen compounds was to
sensitise the cells to current treatments (i.e. TMZ chemotherapy and
radiotherapy) by down-regulating levels of MGMT protein, which in the short
term, should not be cytotoxic to cells.
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4.3 Results
4.3.1 Using custom gene signatures, rapamycin and LY294002 to identify
novel functions of compounds
Table 4.1 lists the custom gene changes I used to mine for compounds and
Tables 4.2 and 4.3 show which gene changes were induced by treatment of
cells with rapamycin and LY294002 respectively. I chose the 17 genes in the
custom gene list as they either directly affect MGMT expression or PI3K/mTOR
signalling. I also wanted to see if a gene expression profile that had changes in
these specific genes would identify similar compounds to the rapamycin and
LY294002 queries, as well as the TMZ resistant GBM patient samples. These
gene changes define the compounds and were the “signatures” I used to search
the database. Although the search generated 50 compounds as a result of the
query search, I only focused on those that had a known effect on the mTOR
signalling pathway, as these were of primary interest for my project because this
pathway is commonly upregulated in GBM cells. The full list of compounds
produced can be found in the Appendix. As shown in the Venn diagram
(Fig.4.1), the only compounds that produced positive connections to all query
profiles (rapamycin, LY294002 and the custom gene list containing 17 genes)
were DAPH, beta escin (both of which are tyrosine kinase receptor inhibitors
[246,247]) and resveratrol, which has been suggested as an AMPK activator
[248]. I also screened thalidomide and thioridazine for potential benefits as they
were both identified by the connectivity mapping, and I found thalidomide in
particular to be of interest as it is a known angiogenesis inhibitor and is also
being currently used for chemotherapy.
4.3.2 Connectivity mapping using KU0063794 and A769662
To do this I created my own microarray gene signatures (as described in the
Materials and Methods), by treating MCF7 cells with 10M KU0063794 or 20M
A769662 for 6 hours. I then used these gene expression profiles for connectivity
mapping (Fig.4.2). Interestingly, the resulting connections did contain
compounds that had been identified both in the connectivity mapping
Table 4.1 Custom gene list
The connectivity mapping database was queried using a custom gene expression profile. The 
genes were chosen either because they are known to be mutated in GBM and/or because 
they influence cap dependant translation. 
Gene name Fold change
MGMT -1
PIK3CA -1
EIF4G1 -1
EIF4G2 -1
EIF4G3 -1
EIF4E -1
EIF4A1 -1
EIF4A2 -1
EIF4A3 -1
EIF4B -1
EIF4EBP1 1
FRAP1 -1
AKT1 1
MAPK1 -1
PTEN -1
TSC1 1
TSC2 1
Table 4.2 Top 30 most changed genes in MCF7 cells treated with rapamycin
The top 30 genes that had the highest fold change in MCF7 cells treated with 0.1mM rapamy-
cin for 6 hours compared to untreated MCF7 cells. 
Gene name Fold change
TXNIP 11887.6
IFRD1 -11689.96
JMJD6 -11454.92
EIF5 -11388.88
HBP1 11138.44
CCDC86 -10891.68
KLHL24 10715.28
RGS16 -10681.84
CCDC28A 10633.48
CCNG2 10628.68
RRS1 -10525.48
NOL1 -10521.4
GPRC5A 10429.8
ARPC5L -10370.72
HSPC111 -10293.8
UTP18 -10280.68
HSPH1 -10092.72
DNAJA1 -9909.68
MAK16 -9786.32
CABC1 9772.68
PIGV 9757.84
DDX21 -9756.44
BNIP3L 9749
YPEL5 9582.16
MRPS12 -9474.08
TARS -9453.56
PUS1 -9410.16
BYSL -9398.24
LOC100133166 9391.44
Table 4.3 Top 30 most changed genes in MCF7 cells treated with LY294002
The top 30 genes that had the highest fold change in MCF7 cells treated with 10mM 
LY294002 for 6 hours compared to untreated MCF7 cells. 
Gene name Fold change
TXNIP 12820.46154
CCNG2 12794.19231
HIST1H3H 12667.19231
DNAJA1 -12646.34615
HBP1 12631.42308
HIST1H2BC 12545.07692
CCDC86 -12503.84615
SFN -12454.69231
BTG1 12416.34615
HSPH1 -12379.57692
RRS1 -12374.61538
PHLDA2 -12362.65385
PPIF -12356.84615
RRP15 -12356.15385
UTP18 -12300.26923
TCF3 -12269
CTPS -12241.84615
CCDC28A 12233.07692
HIST2H2BE 12232.76923
IFRD1 -12231.5
JMJD6 -12224.19231
HIST1H2BD 12190.61538
HIST1H2AC 12167.69231
IER3 -12136
FARSA -12082.84615
DNAJB1 -12053.73077
EIF5 -12037.03846
MARS -11881.69231
HSPA1A -11879.80769
Figure 4.1 Candidate drugs derived from connectivity mapping
The cMap build 2 reference database was searched for chemicals that had a positive correla-
tion with gene signatures obtained from microarray data of MCF7 cells treated for 6 hours with 
10mM LY294002 or 0.1mM rapamycin. The top 30 genes in each treatment that had the highest 
fold change compared to an untreated control were used to define the query gene signatures. 
The database was also used to search for gene changes that showed a positive correlation 
with a custom generated gene list (Table 4.1). The Venn diagram shows which chemicals were 
derived from which searches in the database and indicates where similar results were found. 
Figure 4.2 Connectivity mapping results derived from ‘in house’ KU0063794 and   
 A769662 treatment of cells
MCF7 cells were incubated with 10mM KU0063794 or 20mM A769662 for 6 hours. A genome-
wide mRNA microarray analysis was performed on treated and untreated cells using the 
Illumina platform, as described. The top 30 genes in each treatment that had the highest fold 
change compared to those observed from untreated cells were identified and used to define 
the query gene signatures for each chemical (see appendix).  The cMap build 2 database was 
searched for other chemicals that showed a positive correlation to gene signatures obtained 
with KU0063794 and A769662 (see appendix for full list). The Venn diagram shows matched 
chemicals that have been suggested to also affect the PI3K/mTOR pathway. 
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experiment using rapamycin, LY294002 and the custom gene signature, and the
connectivity mapping performed on the human TMZ-resistant GBM patient
samples. It was also drawn to my attention that many of the compounds with
high connections to the query gene signatures in these connectivity mapping
experiments displayed inhibitory effects on neurotransmitter transduction and
many were also antihistamines in the piperazine family of chemicals. However,
these compounds were not carried forward as they have no known connection
to mTOR signalling. Table 4.4 summarises the compounds that were identified
through connectivity mapping; these data also show which query gene signature
produced that result, and what the known properties of the compounds are (see
Appendix for more details).
4.3.3 Resveratrol does not significantly affect mTOR signalling, but does
affect cell cycle progression
Resveratrol is a phytoestrogen [249] that is found in low levels in foods, such
as red grape skins and Japanese knotweed roots. Resveratrol was initially
trialled at multiple concentrations to ascertain whether it was cytotoxic to T98G
cells. Cells were incubated for 24 hours and cell viability monitored by MTS
assay. As shown in Figure 4.3A, even at high concentrations mitochondrial
function assays showed no toxicity to resveratrol. As resveratrol has been
suggested to activate AMPK, I monitored mTOR signalling as a read-out for the
activation of AMPK [248]. Cells were incubated with 25M resveratrol over a
period of 72 hours, cell extracts were prepared, and Western blotting was
carried out (Fig.4.3B). These data show that resveratrol did not affect the
phosphorylation status of 4E-BP1 (lanes 2-5 vs. lane 1); suggesting that under
these conditions, in T98G cells, resveratrol did not activate AMPK. Resveratrol
did not affect the steady state level of MGMT protein, did not promote the
phosphorylation of eIF2or increase the phosphorylation of AMPK at Thr172
(data not shown) Figure 4.3C shows that similar results were obtained when
cells were incubated with resveratrol in the absence or presence of TMZ.
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Figure 4.3 Resveratrol does not inhibit mTOR, but does affect cell cycle progression
Panel A. T98G cells were incubated with different concentrations of resveratrol for 24 hours 
and A cell viability was assessed using an MTS assay as described in Materials and Methods. 
Values are expressed relative to that obtained in untreated cells (set at 100%). Panel B. Cells 
were incubated in the presence of 25mM of resveratrol for 0-72 hours (lanes 1-5). Extracts 
were prepared and aliquots containing 10mg of protein were resolved by SDS-PAGE and pro-
teins visualised by Western blotting using the antiserum indicated (n=2). Panel C. Cells were 
incubated in the absence (lane 1) or presence (lanes 2-5) of 10mM TMZ for 24 hours with dif-
ferent concentrations of resveratrol (lanes 3-5). Extracts were prepared and aliquots contain-
ing 10mg of protein were resolved by SDS-PAGE and proteins visualised by Western blotting 
using the antiserum indicated (n=2). Panel D. Cells were treated with 25mM of resveratrol for 
24 hours and then harvested for FACS analysis, as described in Materials and Methods. Error 
bars are the S.D (n=3). 
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To determine if resveratrol had any effect on cell cycle progression in T98G
cells, cultures were incubated with resveratrol for 24 hours and the cells were
processed for FACS analysis (Fig.4.3D). Following incubation with resveratrol
for 24 hours, there was a 20% increase in cells in S phase, and a small
decrease in cells in G1 phase and little increase in cells with sub-G1 DNA
content. S phase cell cycle arrest with high concentrations (300M) of
resveratrol has also been seen in other cancer cell lines [250]. However, under
such conditions, there was an increase the cytotoxicity of the drug, reflected in
an increased number of cells with sub-G1 DNA content. As resveratrol showed
no effect on mTOR signalling or on MGMT protein levels, the compound was
not considered further here.
4.3.4 Beta escin is cytotoxic to T98G cells, even at low concentrations
Beta escin is composed of a mixture of triterpenoid saponins and is found in
the seeds of the horse chestnut plant (Aesculus hippocastanum). Beta escin
has been implicated as a receptor tyrosine kinase (RTK) inhibitor [247], and was
therefore investigated for its effect on mTOR signalling. As described above,
cells were incubated for 24 hours with different concentrations of compound and
cell viability monitored by MTS assay. As shown in Figure 4.4A, even at
concentrations below 5M, beta escin was cytotoxic; increased concentrations
of beta escin resulted in 70% cell death at 20M levels. Cells were incubated
with 1M beta escin over a period of 72 hours, cell extracts were prepared, and
Western blotting was carried out. As shown in Figure 4.4B, beta escin had little
effect on the phosphorylation of 4E-BP1, eIF2or the steady state levels of
MGMT. Mitochondrial toxicity assays carried out in parallel (Fig.4.4C) indicated
that the cells were no longer viable after 72 hours of treatment with 1M of beta
escin. Consequently, as the cytotoxicity of beta escin was deemed to be too
great, this compound was not used in further work described here.
AFigure 4.4 Beta escin is cytotoxic to T98G cells
Panel A. T98G cells were treated with different concentrations of Beta escin for 24 hours and  
cell viability was assessed using an MTS assay as described in Materials and Methods. Values 
are expressed relative to those obtained in untreated cells (set at 100%). A standard TTest was 
performed and p values were assigned limits where *<0.05, **<0.005 and ***<0.001. Panel B. 
Cells were incubated in the presence of 1mM of Beta Escin for 0-72 hours (lanes 1-5). Extracts 
were prepared and aliquots containing 10 mg of protein were resolved by SDS-PAGE and 
proteins visualised by Western blotting using the antiserum indicated (n=3). Panel C. Cells 
were treated as in Panel B and cell viability was assessed using an MTS assay as described 
in Materials and Methods.  Cell viability is expressed relative to those obtained in untreated 
cells (set at 100%). A standard TTest was performed and p values were assigned limits where 
*<0.05, *<0.005 and ***<0.001.
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4.3.5 A769662 treatment of cells promotes protein synthesis and the
hyperphosphorylation of 4E-BP1
A769662, (6,7-Dihydro-4-hydroxy-3-(2'-hydroxy[1,1'-biphenyl]-4-yl)-6-oxo-
thieno[2,3-b]pyridine-5-carbonitrile), is known to be a potent activator of AMPK,
reflecting its ability to allosterically bind AMPK and prevent dephosphorylation of
the kinase [251]. The compound was not derived directly from the connectivity
mapping study; however, as many of the chemicals that produced strong
connections to PI3K/mTOR inhibitors also displayed activity towards AMPK, a
direct AMPK activator was chosen to investigate this relationship in glioblastoma
cells. Cells were incubated for 24 hours and cell viability monitored by MTS
assay. As shown in Figure 4.5A, at concentrations up to 20M, A769662 was
not toxic. However, a 10% decrease (Student’s t-test, p<0.05) in mitochondrial
toxicity was seen in cells treated with 50M A769662 compared to an untreated
control, this might reflect the high level of DMSO present in the cultures when
A769662 was used at a high concentration. To look at the effect of A769662 on
PI3K/mTOR signalling, cells were incubated for different times in the presence
of 20M A769662, extracts prepared and the phosphorylation of 4E-BP1
monitored by Western blotting. Figure 4.5B shows that A769662 had little effect
on the phosphorylation status of 4E-BP1, even over 72 hours, indicating that it is
not affect mTORC1 signalling in T98G cells under these conditions. Levels of
phosphorylated eIF2 did not increase over 48 hours and may have decreased
at 72 hours incubation with A769662. However, a reduction in the steady state
levels of MGMT protein was observed as the incubation time increased (Panel
B, lanes 2-4 vs. lane 1), suggesting that A769662 warranted further
investigation.
As with described above, these assays were repeated with different final
concentration of A769662, in the absence or presence of 10M TMZ. Cells were
incubated for 24 hours and 4E-BP1 phosphorylation, eIF2phosphorylation and
steady state levels of MGMT protein levels monitored by Western blotting. As
shown in Figure 4.5C, in contrast to A769662 or TMZ alone (lanes 1 and 2,
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DFigure 4.5 Incubation of cells with A769662 leads to hyperphosphorylation of 4EBP1  
 when combined with TMZ
Panel A. T98G cells were treated with different concentrations of A769662 for 24 hours and  
cell viability was assessed using an MTS assay as described in Materials and Methods. 
Values are expressed relative to those obtained in untreated cells (set at 100%). A stand-
ard TTest was performed and p values were assigned limits where *<0.05, **<0.005 and 
***<0.001. Panel B. Cells were incubated in the presence of 20mM A769662 for 0-72 hours 
(lanes 1-5). Extracts were prepared and aliquots containing 10mg of protein were resolved by 
SDS-PAGE and proteins visualised by Western blotting using the antiserum indicated (n=3). 
Panel C. Cells were incubated in the absence (lane 1) or presence of 10mM TMZ (lanes 2-5), 
in combination with different concentrations of A769662 (lanes 3-5) for 24 hours. Extracts 
were prepared and aliquots containing 10mg of protein were resolved by SDS-PAGE and 
proteins visualised by Western blotting using the antiserum indicated (n=3). Panel D. Cells 
were incubated with 10mM TMZ, combined with different concentrations of A769662 and one 
hour prior to harvesting, cells were incubated with 10µCi/ml [35S] methionine, as described in 
Materials and Methods. Extracts were prepared and incorporation of radioactive methionine 
into protein determined as cpm/mg protein; results are presented as a % of the rate obtained 
in cells incubated in the absence of A769662 and TMZ. Error bars are the S.D (n=3). A 
standard TTest was performed and p values were assigned limits where *<0.05, **<0.005 
and ***<0.001.
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respectively), 25M A769662 combined with 10M TMZ (lane 5) did not result in
a change in MGMT protein levels but did cause the hyperphosphorylation of 4E-
BP1, and decreased levels of eIF2phosphorylation. To complement this, I also
measured the rate of protein synthesis in the cells. Figure 4.5D shows that
incubation of T98G cells with increasing concentrations of A769662 actually
stimulated translation. The reasons for this are unclear but might reflect the
finding that levels of eIF2 phosphorylation decreased and the
hyperphosphorylation of 4E-BP1 was maintained under these conditions
(Fig.4.5B).
4.3.6 Incubation of cells with DAPH leads to dephosphorylation of 4E-BP1
and reduced rates of protein synthesis
DAPH (4,5-dianilinophthalimide) is a selective EGFR inhibitor, that also
inhibits  and  fibril formation associated with Alzheimer’s disease [246]. RTK
inhibitors can often be cytotoxic due to the broad range of RTKs that they can
affect. To assess the cytotoxicity of DAPH in T98G cells, a cell viability assay
was carried out using increasing final concentrations of DAPH over 24 hours.
The data shown in Figure 4.6A indicates that at the concentrations employed
here, DAPH did not cause a loss of cell viability. To ascertain the effect of DAPH
on PI3K/mTOR signalling, cells were incubated with 5M of DAPH for 24 hours,
extracts prepared and the phosphorylation of 4E-BP1 monitored by Western
blotting (Fig.4.6B). These data show that there was a clear dephosphorylation of
4E-BP1 between 48-72 hours (lanes 4 and 5), as visualised by the increased
mobility of 4E-BP1 on SDS-PAGE, indicating that mTORC1 was inhibited. Up to
24 hours, there appeared to be an increase in both MGMT protein levels and
eIF2phosphorylation (lanes 2-3 vs. lane 1), but levels of both decreased at 48
and 72 hours (lanes 4-5 vs. lane 3). When cells were incubated with both DAPH
and TMZ (Fig.4.6C), the steady state level of MGMT protein was not reduced,
and levels of eIF2phosphorylation also was not affected (lanes 4-5 vs. lanes 1
and 2). Surprisingly, in contrast to DAPH alone (B), under these conditions the
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DFigure 4.6 Incubation of T98G cells with DAPH leads to dephosphorylation of 4EBP1  
 when used alone, but not when used in combination with TMZ
Panel A. T98G cells were treated with different concentrations of DAPH for 24 hours and  
cell viability was assessed using an MTS assay as described in Materials and Methods. 
Values are expressed relative to those obtained in untreated cells (set at 100%). A stand-
ard TTest was performed and p values were assigned limits where *<0.05, **<0.005 and 
***<0.001. Panel B. Cells were incubated in the presence of 5mM of DAPH for 0-72 hours 
(lanes 1-5). Extracts were prepared and aliquots containing 10mg of protein were resolved by 
SDS-PAGE and proteins visualised by Western blotting using the antiserum indicated (n=3). 
Panel C. Cells were incubated in the absence (lane 1) or presence of 10mM TMZ (lanes 2-5), 
in combination with different concentrations of DAPH (lanes 3-5) for 24 hours. Extracts were 
prepared and aliquots containing 10mg of protein were resolved by SDS-PAGE and proteins 
visualised by Western blotting using the antiserum indicated (n=3). Panel D.Cells were incu-
bated in 10mM TMZ combined with different concentrations of DAPH and one hour prior to 
harvesting, cells were incubated with 10µCi/ml [35S] methionine, as described in Materials and 
Methods. Extracts were prepared and incorporation of radioactive methionine into protein 
determined as cpm/mg protein; results are presented as a % of the rate obtained in cells incu-
bated in the absence of DAPH and TMZ. Error bars are the S.D (n=3). A standard TTest was 
performed and p values were assigned limits where *<0.05, **<0.005 and ***<0.001
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level of 4E-BP1 phosphorylation did not decrease, suggesting that mTORC1
signalling was unaffected here. Incubation of T98G cells with DAPH resulted in
an inhibition of protein synthesis (Fig.4.6C), even at the lowest concentrations
tested. As this could not be directly ascribed to either changes in 4E-BP1
phosphorylation or eIF2phosphorylation, the reason for this inhibition is
unclear.
4.3.7 KU0063794 selectively inhibits mTOR and is not cytotoxic to cells
KU0063794 is a small molecule kinase inhibitor, which inhibits both mTOR
complexes (mTORC1/mTORC2) whilst displaying a reduced activity towards
other kinases [252]. Its specificity is very similar to Torin 1, the mTOR inhibitor
used in earlier experiments. Cell viability assays (Fig.4.7A) indicated that, over a
period of 24 hours, KU0063794 was only cytotoxic to cells when used at
concentrations greater than 20M. This was demonstrated by a 20% decrease
(Student’s t-test, p<0.05) in dye produced compared to the untreated control.
Western blotting analysis confirmed that over 72 hours, incubation of cells with
10M KU0063794 promoted the dephosphorylation of 4E-BP1, reduced levels
of eIF2phosphorylation and yet maintained MGMT protein levels (Fig.4.7B).
These data are consistent with KU0063794 being an effective inhibitor of mTOR
signalling.
4.3.8 Thalidomide does not have a significant effect on T98G cell
signalling or cell viability
The next compound used in the initial screening programme shown here, and
suggested by the connectivity mapping study, was thalidomide. Thalidomide is
famously known as a teratogen. It is now known to also display anti-
inflammatory and anti-proliferative effects, as well as inhibiting TNF- synthesis
[253], but currently has no known activity towards the PI3K/mTOR pathway. Its
current use as a treatment of multiple myeloma [254] prompted me to include it
in my initial screening of compounds which might alter the steady state level of
MGMT protein in T98G cells. Unfortunately, as well as showing no cytotoxic
AFigure 4.7 KU0063794 inhibits mTOR signalling and is not cytotoxic to the cells
Panel A. T98G cells were treated with different concentrations of KU0063794 for 24 
hours and  cell viability was assessed using an MTS assay as described in Materials and          
Methods. Cell viability is expressed relative to that obtained in untreated cells (set at 100%). 
A standard TTest was performed and p values were assigned limits where *<0.05, **<0.005 
and ***<0.001. Panel B. Cells were incubated in the presence of 10mM of KU0063794 for 
0-72 hours (lanes 1-5). Extracts were prepared and aliquots containing 10mg of protein were 
resolved by SDS-PAGE and proteins visualised by Western blotting using the antiserum indi-
cated (n=3). 
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effects on these cells (Fig.4.8A), it did not show any significant effect on MGMT
protein levels, 4E-BP1 phosphorylation or eIF2phosphorylation (Fig.4.8B). A
similar lack of effect was seen even when the compound was used in the
presence of TMZ (C). Consequently, I decided not to use this compound in any
further studies reported here.
4.3.9 Thioridazine inhibits protein synthesis when used in conjunction
with TMZ
The final compound that I used as part of this preliminary screening process
was thioridazine, a dopamine receptor antagonist that belongs to the family of
drugs known as the phenothiazines. It has been widely used to treat psychotic
disorders such as schizophrenia and psychosis [255];however, it has more
recently been considered as a possible cancer therapeutic as it has been shown
to induce apoptosis by inhibiting the PI3K/Akt/mTOR pathways in HeLa cells
[256]. To look at the effect of thioridazine on cell viability, cells were incubated
with increasing final concentrations of the compound over 24 hours. The data
shown in Figure 4.9A indicates that at the concentrations employed here,
thioridazine did not cause a loss of cell viability. To look at potential effects on
mTOR signalling and MGMT protein levels, cells were incubated with different
final concentrations of thioridazine. Western blotting did not show any significant
effect on MGMT protein levels, 4E-BP1 phosphorylation or on
eIF2phosphorylation (data not shown). Additional assays were carried out with
thioridazine in the presence if TMZ. When cells were treated with a combination
of thioridazine and TMZ for 24 hours, the level of phosphorylation of 4E-BP1
was not changed. In contrast, the combination of thioridazine and TMZ
decreased the steady state levels of MGMT protein and increased the
phosphorylation of eIF2 (Fig.4.9B lanes 4-5 vs. lane1). As the data presented
in Panel B suggested that thioridazine might have an effect on protein synthesis
rates by the level of eIF2phosphorylation, cells were incubated with [35S]
methionine at the end of incubating cells with thioridazine for 24 hours. As
shown in Figure 4.9C, thioridazine promoted a decrease in protein synthesis
AFigure 4.8 Thalidomide does not have a significant effect on mTOR signalling in T98G  
 cells
Panel A. T98G cells were treated with different concentrations of Thalidomide for 24 hours 
and  cell viability was assessed using an MTS assay as described in Materials and Methods. 
Values are expressed relative to those obtained in untreated cells (set at 100%). A stand-
ard TTest was performed and p values were assigned limits where *<0.05, **<0.005 and 
***<0.001. Panel B. Cells were incubated in the presence of 10mM of Thalidomide for 0-72 
hours (lanes 1-5). Extracts were prepared and aliquots containing 10mg of protein were re-
solved by SDS-PAGE and proteins visualised by Western blotting using the antiserum indi-
cated (n=2). Panel C. Cells were incubated in the absence (lane 1) or presence (lanes 3-5) 
of 10mM TMZ for 24 hours with different concentrations of Thalidomide (lanes 2-5). Extracts 
were prepared and aliquots containing 10mg of protein were resolved by SDS-PAGE and pro-
teins visualised by Western blotting using the antiserum indicated (n=2).
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AFigure 4.9 Thioridazine inhibits protein synthesis when used in combination with TMZ
Panel A. T98G cells were treated with different concentrations of thioridazine for 24 hours and  
cell viability was assessed using an MTS assay as described in Materials and Methods. Values 
are expressed relative to those obtained in untreated cells (set at 100%). A standard TTest was 
performed and p values were assigned limits where *<0.05, **<0.005 and ***<0.001. Panel B. 
Cells were incubated in the absence (lane 1) or presence of 10mM TMZ (lanes 2-5), in combina-
tion with different concentrations of thioridazine (lanes 3-5) for 24 hours. Extracts were prepared 
and aliquots containing 10mg of protein were resolved by SDS-PAGE and proteins visualised by 
Western blotting using the antiserum indicated (n=3). Panel C. Cells were incubated with 10mM 
TMZ, combined with different concentrations of thioridazine and one hour prior to harvesting, 
cells were incubated with 10µCi/ml [35S] methionine, as described in Materials and Methods. 
Extracts were prepared and incorporation of radioactive methionine into protein determined 
as cpm/mg protein; results are presented as a % of the rate obtained in cells incubated in the 
absence of thioridazine and TMZ. Error bars are the S.D (n=3). A standard TTest was performed 
and p values were assigned limits where *<0.05, **<0.005 and ***<0.001.
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rates compared to untreated cells when treated with a combination of
Thioridazine and TMZ over a 24 hour time period. Yet this compound did not
show any other positive effects on T98G cell MGMT levels during further
experiments (data not shown), and so was not considered effective for this
project.
4.4 Summary
 The compounds that reduced MGMT protein levels over 72 hours were
beta escin, A769662 and DAPH
 The compounds that were effective were identified using known PI3K,
mTOR inhibitors, custom gene signatures and the TMZ-resistant GBM
patient data
 Beta escin is toxic and therefore was not suitable for future studies.
4.5 Conclusions
Preliminary experiments with the compounds identified with connectivity
mapping were used to establish the suitability of each compound for further
work. The results of these initial screens suggested that only three compounds
were effective at reducing MGMT protein levels whilst remaining non-cytotoxic
to cells; DAPH, A769662 and KU0063794. The main aim of using the
connectivity mapping database was to find compounds that could reduce rates
of MGMT protein synthesis while remaining non-cytotoxic when used by
themselves. The summary of drug treatments outlined in Figure 4.10A shows
the results of cell viability assays performed on cells treated with differing
compounds for 24 hours, both when used alone and when combined with 10M
TMZ. Here it is immediately obvious that beta escin is unsuitable for further work
as it is the only compound that is cytotoxic over this short incubation time. The
data in Figure 4.10B shows a comparison of the effects of the compounds alone
and in combination with TMZ on protein synthesis. Here it is noticeable that
thalidomide has no significant effect on protein synthesis rates, both when used
alone or when used in combination with TMZ. Although resveratrol did have a
AFigure 4.10 Effect of different drugs on cell viability and rates of protein synthesis
Panel A. T98G cells were incubated with set concentrations of drugs; Resveratrol 25mM, 
Thalidomide 10mM, Beta Escin 1mM, DAPH 5mM, KU0063794 10mM, A769662 20mM, 
Thioridazine 5mM and TMZ 10mM and incubated for 24 hours either alone, or in combina-
tion with 10mM TMZ.  Cell viability was assessed using an MTS assay as described in 
Materials and Methods and is expressed relative to that obtained in untreated cells (set at 
100%). Error bars are the S.D (n=3). A standard TTest was performed and p values were 
assigned limits where *<0.05, **<0.005 and ***<0.001. Panel B. T98G cells were incubated 
as in (A) and one hour prior to harvesting, cells were incubated with 10µCi/ml [35S] methio-
nine, as described in Materials and Methods. Extracts were prepared and incorporation of 
radioactive methionine into protein determined as cpm/mg protein; results are presented 
as a % of the rate obtained in cells incubated in the absence of drug treatments. Error 
bars are the S.D (n=3). A standard TTest was performed and p values were assigned limits 
where *<0.05, **<0.005 and ***<0.001.
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Untreated Resveratrol Thalidomide Beta escin DAPH KU0063794 A7969662 Thioridazine TMZ
Table 4.4 Summary of initial compounds trialled, and which candidates are appropriate  
 for continued research
A summary of initial compounds trialled as a result of connectivity mapping and the decision as 
to whether to carry on researching them or not. This table summarises the effect the com-
pound has on the cells when used alone, not in conjunction with TMZ
Chemical Continuation decision Effect on MGMT 
protein levels
Additional notes
Resveratrol Discontinue No effect No significant effect on 
mTOR signalling 
Thalidomide Discontinue No effect No significant effect on 
mTOR signalling
Beta Escin Discontinue No effect Cytotoxic to cells, even in 
low doses
DAPH Continue Small reduction mTOR inhibition
KU0063794 Continue No effect Good positive control for 
mTOR inhibition
A769662 Continue Reduction Lack of mTOR inhibition 
is interesting - how is it af-
fecting the MGMT levels?
Thioridazine Discontinue No effect Protein synthesis inhibi-
tion
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slight effect on protein synthesis rates, and was not cytotoxic, the lack on an
effect on mTOR signalling meant the compound was not used any further in my
study. A summary of the compounds carried on to the next stage of analysis can
be found in Table 4.4.
Chapter V
Characterising the effect of KU0063794, 
DAPH, A769662 and TMZ on cellular signalling 
and protein synthesis
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5 Characterising the effect of selected compounds on cellular signalling
and protein synthesis
5.1 Aims
 To characterise how the compounds are affecting cell signalling
 To understand how the compounds are affecting MGMT protein levels
 To determine if the compounds sensitise the cells to TMZ
5.2 Introduction
The next objective after using the connectivity mapping technique to find
compounds that would potentially modulate MGMT was to characterise how the
compounds were affecting the T98G glioblastoma cells. For this, I set out to
determine the effect the compounds had on cell signalling, MGMT protein
localisation, cap dependent translation and protein synthesis rates. Establishing
which specific proteins the compounds were affecting, as well as trying to
determine whether the compounds sensitised the cells to TMZ was also
important. Identifying proteins that are being affected by the compounds could
indicate which cellular signalling pathways were being interfered with. To this
end, T98G cells were incubated with the indicated concentration of KU0063794,
DAPH or A769662, both alone and in combination with TMZ for up to 72 hours
and extracts were prepared as described in the Materials and Methods. Western
blotting was used to determine the effect of compounds on targets in T98G
cells.
5.3 Results
5.3.1 Identifying how the compounds affect cellular signalling in T98G
cells
T98G cells were incubated with 10M KU0063794 alone (Fig.5.1 A) or in
combination with 10M TMZ (Panel B) for the time indicated in the figure.
Western blotting analysis demonstrates that phosphorylation of Akt on Thr308
increases upon inhibition of mTOR signalling in comparison to untreated cells
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Figure 5.1 All compounds affect proteins associated with the mTOR signalling        
 pathway
Panel A. T98G cells were incubated in the absence (lane 1) or presence of 10mM 
KU0063794 (n=3). Panel C. 5mM DAPH (n=3) Panel E. 20mM A769662 (n=3) for 12-72 
hours (lanes 2-5). Extracts were prepared and aliquots containing 10mg of protein were re-
solved by SDS-PAGE and proteins visualised by Western blotting using the antiserum indi-
cated. Panels B, D, F Cells were treated as in (A,C,E), but treatments were combined with 
10mM TMZ (n=3). Panel G. Cells were treated with 10mM  TMZ alone for 0-72 hours (lanes 
1-5). Extracts were prepared and aliquots containing 10mg of protein were resolved by SDS-
PAGE and proteins visualised by Western blotting using the antiserum indicated (n=3).
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(lanes 2-5 vs. lane 1).There was little increase in the phosphorylation (and
hence activation) of p38MAPK, AMPK or eIF2 phosphorylation. These data
suggest that prolonged incubation with KU0063794 may lead to the activation of
PI3K signalling, as described for rapamycin [257]. The decrease in
phosphorylation of p70 S6K at Thr389 in cells treated with either KU0063794
alone (A) or in conjunction with TMZ ( B) compared to the untreated control
(lanes 2-5 vs. lane 1) reaffirms the inhibition of the mTOR signalling pathway, as
this specific phosphorylation site is directly controlled by mTOR. Surprisingly,
incubation of cells with both KU0063794 and TMZ delayed the
dephosphorylation of p70S6K Thr389 relative to that seen with KU0063794
alone. In T98G cells incubated with both KU0063794 alone and in combination
with TMZ, MGMT levels did not change, (Fig.5.1A).
In cells incubated with 10M TMZ alone for 24 hours, there were some
changes in the activity of intracellular signalling pathways and the steady state
level of MGMT protein (Fig.5.1G). The most obvious was a transient increase in
p70S6K phosphorylation and a general increase in the activation of Akt, and the
absence of stress kinase and/or eIF2 phosphorylation. The level of MGMT
protein expression dropped dramatically following treatment of cells with TMZ,
reaching a low level at 12 hours; this probably reflects the use of MGMT protein
in repairing TMZ-induced DNA damage. However, this level increased as the
incubation time with TMZ progressed (lanes 3-5 vs. lane 2), suggesting that
MGMT may be synthesised actively during this period.
Cells incubated with DAPH alone and in combination with TMZ over 24 hours
(Fig.5.1C and D) only showed a slight increase in Akt 308 phosphorylation. p70
S6K phosphorylation was largely unaffected in cells treated with either DAPH
alone or with TMZ (lanes 2-5 vs. lane 1) and only showed a minor decrease
during the later time points (lanes 4 and 5 vs. lanes 1-3). There was little change
in the phosphorylation (and hence activation) of AMPK under any conditions
with DAPH. The level of MGMT protein varied slightly in cells incubated with
DAPH alone but not when used in combination with TMZ (Fig.5.1 C, D). This
variation was reproducible (data not shown).
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As A769662 has shown in previous cell lines that it is an AMPK activator
[251], it was surprising that when incubated with T98G cells for 24 hours alone
(Fig.5.1E), it did not seem to have an effect on AMPK phosphorylation. There
was a transient increase in AMPK Thr172 phosphorylation and p38MAPK
phosphorylation at 12-24 hours (lanes 2 and 3), which decreased to basal
levels by 48 hours of incubation in the cells incubated with a combination of both
A769662 and TMZ however, there was an increase in phosphorylated AMPK
(Fig.5.1F) which occurred without activation of p38MAPK or eIF2
phosphorylation. These data suggest that A769662 with TMZ activates AMPK
without eliciting a general stress response in T98G cells. However, this
activation of AMPK is not sufficient to promote dephosphorylation of 4E-BP1
mediated by inhibition of mTORC1 signalling. Akt phosphorylation at Thr308
and p70S6K Thr389 phosphorylation both increased transiently in cells treated
with A769662 alone compared to an untreated control (Panel E, lanes 2-5 vs.
lane 1). To a lesser extent, these phosphorylation events were observed in cells
incubated concurrently with TMZ. MGMT protein levels were not affected by
incubation with A769662 (Fig 5.1E, F).
5.3.2 KU0063794 impairs the cells ability to form the eIF4F complex
Inhibition of the mTOR signalling pathway results in 4EBP1 remaining bound
to eIF4E causing it to be unavailable to participate in the eIF4F initiation
complex alongside the helicase eIF4A and the scaffold protein eIF4G. To
ascertain whether or not the cells are able to form this complex after incubation
with KU0063794, DAPH, A769662 or TMZ, cell extracts were prepared and
100g of total protein was mixed with Sepharose beads coupled to m7GTP
(lanes 1 and 3-9). This cap structure emulates that of the mRNA cap on the 5’
end of an mRNA, resulting in eIF4E and associated proteins binding to it. Lysate
from cells incubated in the absence of compounds was mixed with Sepharose
beads lacking an m7GTP cap to serve as a negative control for specific
interaction of recovered proteins with the cap analogue (lane 2). Figure 5.2
(lane 1 vs. 2) shows that the eIF4F complex (eIF4E, eIF4A, eIF4G) and
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Figure 5.2 KU0063794 inhibits eIF4F complex formation, both when used alone and  
 when combined with TMZ
Panel A. T98G cells were incubated for 24 hours in the absence (lanes 1 and 2) or presence 
of 5mM DAPH (lane 3), 10mM KU0063794 (lane 5) or 20mM A769662 (lane 7), either alone or 
in conjunction with 10mM TMZ (lanes 4,6 and 8). Cells were also incubated with 10mM TMZ 
alone (lane 9). Extracts were prepared and aliquots containing 100mg of protein were sub-
jected to m7GTP-Sepharose affinity chromatography as described in Materials and Methods 
(n=3). Sepharose beads lacking an m7GTP cap were also combined with 100mg of untreated 
extract as a negative control (lane 2). eIF4E and associated proteins were recovered and 
resolved by SDS-PAGE and proteins visualised by Western blotting using the antiserum indi-
cated. All lanes were resolved on the same gel. Panel B. Cells were treated as in panel A but 
for 72 hours (n=2). 
U
nt
re
at
ed
S
ep
ha
ro
se
 b
ea
ds
61
eIF4E/4E-BP1 complexes were specifically recovered with the resin. When cells
were incubated with KU0063794 for 24 hours (Fig.5.2A), there was a decrease
in the association of eIF4A and eIF4G recovered with eIF4E (lane 5 vs. lane 1),
suggesting that this initiation complex is not forming. Furthermore, this decrease
in eIF4F complex levels was associated with increased levels of eIF4E
associated with 4E-BP1, and decreased levels of phosphorylated eIF4E. A
similar response was seen when cells were incubated with both KU00663794
and TMZ (lane 6 vs. lane 5). Incubation of cells with DAPH, in the absence or
presence of TMZ has a similar, but less pronounced effect on eIF4F complex
levels. In contrast, incubation of the cells with A769662 in the absence or
presence of TMZ, or indeed TMZ alone, has little effect on eIF4F complex levels
or eIF4E phosphorylation (lanes 7-9 vs. lane 1).
To investigate eIF4E/BP-1 levels further, cells were incubated with
compounds, without and with TMZ for 72 hours and eIF4E and associated
proteins recovered as above. Figure 5.2B shows that at this time point, in
general, results were similar to those seen at 24 hours. However, effects of
KU0063794 on eIF4E/4E-BP1 levels were less pronounced relative to untreated
cells (lanes 5 and 6 vs. lane 1). These data suggest that cells have adapted to
the presence of the compound over this period of time. Alternatively, as
recovery of eIF4E here was somewhat variable, this could also reflect a problem
with protein complex recovery from the resin.
5.3.3 MGMT protein does not re-localise in cells treated with compounds
MGMT protein is over-expressed in T98G cells relative to other glioblastoma
cell lines [258,259] and we show that it is predominantly nuclear in this cell line.
With increased levels of MGMT protein in these cells, if the protein were to
differentially localise between cellular compartments during incubation with
chemotherapeutic agents or other compounds, it could give us an insight in to
how the steady state level of the protein is being regulated. Taking this in to
account, cells were incubated with compounds for 24 hours, at the
concentrations stated in Figure 5.3. Confocal imaging analysis was then
AB
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Figure 5.3 MGMT does not relocalise in cells treated with DAPH, KU0063794 or   
 A769662
Panel A. Untreated T98G cells were fixed and permeabilised as described in Materials and 
Methods. Proteins were visualised using fluor conjugated anti serum against MGMT, actin 
and DNA, as indicated. Images were collected on a Zeiss Axiovert LSM510 scanning confo-
cal microscope using a ×100 objective. Panel B. Untreated T98G cells were fixed and perme-
abilised as described in Materials and Methods. Proteins were incubated with the secondary 
antibody only. Panel C. Untreated U87- MG cells were fixed and permeabilised as described 
in Materials and Methods. Proteins were visualised using fluor conjugated anti serum against 
MGMT, or secondary antibody only and DNA, as indicated. Panel D. T98G cells were incu-
bated in the absence or presence of 5mM DAPH, 10mM KU0063794 or 20mM A769662, either 
alone or in conjunction with 10mM TMZ for 24 hours. Cells were also treated with 10mM TMZ 
for 24 hours. Cells were then fixed, permeabilised and processed for IF analysis of MGMT, 
as described in Materials and Methods. Images were collected on a Zeiss Axiovert LSM510 
scanning confocal microscope using a ×100 objective. The localisation of MGMT was quanti-
fied in the nuclear and cytoplasmic fractions from three separate preparations using ImageJ. 
Error bars are the S.D (n=3). A standard T Test was performed and p values were assigned 
limits where *<0.05, **<0.005 and ***<0.001.
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performed to determine if the percentage of MGMT protein in the nucleus
versus the cytoplasm changed between untreated cells and cells incubated with
compounds. The data shown in panel A confirm that although staining for
MGMT can be clearly seen in the cytoplasm, the protein is enriched in the
nuclear compartment. This did not change appreciably when cells were
incubated with any of the compounds, with or without TMZ (data not shown). To
ensure the primary and secondary antibodies were not binding to cellular
proteins non-specifically, T98G cells were incubated with secondary antibody
and DAPI only (Fig.5.3B). These data clearly show the presence of the DNA but
no other signal, showing the specificity of the antibody used here. In addition, I
have used U87-MG cells which do not express MGMT [260]. As predicted, when
these cells were probed with either primary and secondary antibody or
secondary antibody only alongside DAPI staining ( C), only nuclei were visible,
confirming that I was looking at MGMT protein in the T98G cells. Such data
were quantified from cells incubated in the absence or presence of the
compounds shown, confirming that no significant re-localisation of MGMT
protein was observed under these assay conditions (Fig.5.3D).
5.3.4 MGMT mRNA levels do not change significantly in cells treated with
compounds
The compounds derived from connectivity mapping experiments were chosen
based on their ability to change specific mRNA levels whose protein products
had been linked into mTOR inhibition. However, it was important for me to know
whether the compounds used in my work were mainly regulating protein
synthesis through an inhibition of translation or a down-regulation via a
transcriptional mechanism. To confirm the changes seen in MGMT protein
levels in cells treated with A769662 and DAPH alone were not a reflection of
changes in mRNA levels, qRT-PCR was performed to measure the amount of
MGMT mRNA present in untreated cells compared to mRNA levels in cells
incubated with the compounds for either 24 (Fig.5.4A) or 72 hours (Fig.5.4B).
MGMT mRNA levels were also measured in cells treated with the compounds
AFigure 5.4 MGMT mRNA levels do not change significantly in treated cells
Panel A. Cells were incubated for 24 hours in the absence or presence of 5mM DAPH, 10mM 
KU0063794 or 20mM A769662, either alone or in conjunction with 10mM TMZ for 24 hours as 
indicated. mRNA was extracted from cell extracts as described in Materials and Methods. For 
each treatment, quantitative RT-PCR was used to determine levels of MGMT mRNA relative 
to 18S rRNA, as described. Data are presented as a fold change in mRNA amount relative 
to levels observed in untreated cells. Error bars are the S.D (n=3). A standard T Test was 
performed and p values were assigned limits where *<0.05, **<0.005 and ***<0.001. Panel B. 
Cells were treated as in (A) but for 72 hours.
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treated with KU0063794 and in combination with KU0063794. These
experiments were used to correlate mRNA levels and protein levels across
treatments, to allow the results to be observed in a wider context. Levels of
MGMT mRNA expression were then expressed relative to the levels of 18S
ribosomal RNA in the same cells. As shown, when T98G cells were incubated
with the compounds for 24 hours, there was not a dramatic difference in the
levels of MGMT mRNA relative to those found in cells incubated in the absence
of compounds (Fig.5.4A). However, cells incubated with DAPH or DAPH plus
TMZ did show a 30% reduction (Student’s t-test, p<0.05) in MGMT mRNA which
was significant. Similarly, MGMT mRNA levels relative to those found in cells
incubated in the absence of compounds varied little following a 72 hour
incubation period with the compounds (Fig.5.4B). One exception was when cells
were incubated with both KU0063794 and TMZ, where there was a significant
(Student’s t-test, p<0.05) increase in MGMT mRNA levels, yet this is not
considered a large fold change in mRNA levels and may be a result of cellular
stress as it was only observed in the 72 hour treatment and not the 24 hour
treatment. Overall, these data confirm that the change of MGMT protein levels
in cells treated with the DAPH and A769662 is not likely to be a reflection of
reduced mRNA levels.
5.3.5 Inhibiting mTOR signalling does not fully inhibit eukaryotic
translation
To get a complete picture of events in the cells that are being treated with the
compounds, I needed to look more closely at the actively translating polysomes.
From the connectivity mapping, I already have information providing insight into
the transcriptional effects the compounds have on cells, their ability to change
protein levels and affect protein synthesis, and their effect on eukaryotic
translation initiation. Yet to obtain more information about the functioning cell, I
need to understand how the compounds are affecting the amount of ribosomes
that are actively translating protein. Polysome profiling separates free material,
ribosomal subunits and polysomes to determine the amount of mRNA engaged
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on polysomes and hence actively involved in translation at any point. For this,
T98G cells were incubated with the compounds for 24 hours at the
concentrations specified in the figure legend (Fig.5.5). Cells were then lysed in a
hypotonic lysis buffer and the cell extracts centrifuged through a sucrose
gradient to separate the ribosomal subunits from the polysomes. As shown in
Figure 5.5A, incubation of cells with DAPH had little effect on the recovery of
mRNA in heavy polysomes, suggesting that translation is still occurring quite
efficiently. This was somewhat surprising considering that whilst DAPH only had
a moderate effect on eIF4F levels (Fig.5.2), [35S] methionine incorporation into
protein was reduced to about 20% (Student’s t-test, p<0.005) of that observed in
untreated cells (Fig.4.6).
Cells treated with KU0063794 for 24 hours show an increase in 80S
monosomes compared to the untreated cells. There are also fewer polysomes
in the KU0063794 treated cells compared to the control consistent with an
inhibition of protein synthesis (Fig.4.10B) and decreased eIF4F levels (Fig.5.2).
However, it is important to note that some polysomes are still present in these
cells. In contrast, incubation of cells with either A769662 or TMZ seemed to
have had little effect on the association of mRNA into actively translating
polysomes, suggesting that these compounds do not inhibit translation at 24
hours. This information does correlate with the data obtained with m7GTP-
Sepharose isolation of eIF4F (Fig.5.2A) indicating no change in this complex or
protein synthesis rates (Fig. 4.10B) under these conditions
5.3.6 MGMT mRNA remains in polysomes during mTOR inhibition and
reduced translation initiation
To determine whether the maintenance of MGMT protein in cells treated with
KU0063794 was due to maintenance of MGMT mRNA translation during
reduced eukaryotic initiation and protein synthesis, quantitative RT-PCR was
carried out on the fractions obtained during polysome fractionation as described
in Figure 5.5. The polysome fractions were pooled, so as to measure mRNA in
the free material, the ribosomal subunits and monosomes, the light polysomes
AFigure 5.5 DAPH and KU0063794 both inhibit mTOR, but have different effects on   
 polysome levels
T98G cells were incubated for 24 hours in the absence or presence of 5mM DAPH (Panel A), 
10mM KU0063794 (Panel B), 20mM A769662 (Panel C) or 10mM TMZ (Panel D). Cell extracts 
were prepared and subjected to polysome profiling as described in materials and methods. 
The figure represents 3 separate experiments (n=3). 
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and the heavy polysomes. By measuring the amount of GAPDH and MGMT
mRNA in each of these fractions, it is possible to compare the distribution of
GAPDH mRNA and MGMT mRNA after incubation of cells with compounds for
24 hours. Untreated cells show a similar distribution of GAPDH and MGMT
mRNA across the fractions in the gradient (Fig.5.6A), whereas cells that were
incubated with 10M KU0063794 for 24 hours showed a reduction of GAPDH
mRNA in the polysome fractions and an increase in GAPDH mRNA in the
subunits and free material. Surprisingly, the MGMT mRNA associated with
polysomes was not reduced, even though translation was greatly reduced.
Similar amounts of MGMT mRNA were observed in the light and heavy
polysomes as seen in the untreated cells (Fig.5.6B). The distribution of MGMT
and GAPDH mRNA in cells incubated with A769662 was very similar (Fig.5.6D),
although there was more total RNA extracted from this gradient than any of the
other gradients (data not shown). When cells were incubated with DAPH, there
was a reduction of GAPDH mRNA in the heavy polysome fractions and an
increased recovery in the subunit fraction. Although this reduction of GAPDH
mRNA was observed in the heavy polysome fraction, MGMT mRNA did not
follow the same pattern, and was present in a high percentage in both the light
and heavy polysomes (Fig.5.6C).
.
5.3.7 U87-MG and T98G cells respond to the compounds in similar ways
T98G cells show resistance to TMZ, mainly because they express a high
amount of MGMT protein in comparison to other GBM cell types [258,259]. To
ensure that the effects the selected compounds had on the T98G cells were not
cell-specific, I also used U87-MG cells; these brain tumour-derived human cells
are MGMT null. Therefore, U87-MG cells were incubated with the compounds
for 24 hours (Fig.5.7) and both Western blotting analysis and rates of protein
synthesis were performed on the cells, as described previously.
Western blotting analysis of the extracts derived from U87-MG cells
(Fig.5.7A) suggested that the compounds had a similar effect to those observed
with T98G cells. The dephosphorylation of 4E-BP1 in the cells treated with
AFigure 5.6  MGMT mRNA remains in polysomes during translation initiation inhibition
Cells were incubated for 24 hours in the absence (Panel A) or presence of 10mM KU0063794 
(Panel B), 5mM DAPH (Panel C) or 20mM A769662 (Panel D), lysates were prepared and 
polysomes resolved and fractionated as described in Figure 6.5. The mRNA from pooled frac-
tions was extracted as described in Materials and Methods. For each gradient, quantitative 
RT-PCR was used to determine levels of GAPDH and MGMT mRNA distribution across each 
fraction, with the total mRNA in each gradient set at 100%.  Error bars are the S.D (n=3) of 3 
technical replicates. 
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Figure 5.7 U87-MG cells respond to the compounds in a similar way to T98G cells
Panel A. U87-MG cells were incubated in the absence (lane 1) or presence of 10mM 
KU0063794 (lane 2), 5mM DAPH (lane 4) or 20mM A769662 (lane 6), either alone or in 
conjunction with 10mM TMZ (lanes 3,5 and 7) for 24 hours. Cells were also incubated with 
10mM TMZ alone (lane 8). Extracts were prepared and aliquots containing 10mg of protein 
were resolved by SDS-PAGE and proteins visualised by Western blotting using the antise-
rum indicated (n=2). Panel B. Cells were treated as in (A) and one hour prior to harvesting, 
cells were incubated with 10µCi/ml [35s] methionine, as described in Materials and Methods. 
Extracts were prepared and incorporation of radioactive methionine into protein determined 
as cpm/mg protein; results are presented as a % of the rate obtained in cells incubated in the 
absence of compounds. Error bars are the S.D (n=3). A standard T Test was performed and 
p values were assigned limits where *<0.05, **<0.005 and ***<0.001.
 
U
nt
re
at
ed
%
 o
f c
on
tro
l
** **
**
* ** **
eIF4A
p-eIF2a
MGMT
Akt Thr308
A 1 2 3 4 5 6 7
B
Figure 5.8 Combining KU0063794, TMZ and ionising radiation dramatically reduces  
 MGMT protein levels in T98G cells
Panel A. T98G cells were incubated in the presence of compounds as indicated. KU0063794 
was used at 10mM, DAPH at 5mM, A769662 at 20mM, TMZ at 10mM and Ionising radiation at 
2Gy. Cells were all incubated with compounds for 72 hours, irradiated, then harvested 24 hours 
later. Lysates were resolved by SDS-PAGE and proteins visualised by Western blotting using 
the antiserum indicated (n=2). Panel B. T98G cells were incubated as indicated and one hour 
prior to harvesting, cells were incubated with 10µCi/ml [35S] methionine, as described in Ma-
terials and Methods. Extracts were prepared and incorporation of radioactive methionine into 
protein determined as cpm/mg protein; results are presented as a % of the rate obtained in cells 
incubated in the absence of drug treatments. Error bars are the S.D (n=3). A standard T Test 
was performed and p values were assigned limits where *<0.05, **<0.005 and ***<0.001.
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KU0063794 or KU0063794 plus TMZ (lanes 3 and 4 vs. lane 1) indicated that
mTOR signalling was inhibited. Incubation of these cells with DAPH caused a
slight dephosphorylation of 4E-BP1 (lanes 4 and 5 vs. lane 1), but A769662
(lanes 6 and 7 vs. lane 1) or TMZ (lane 8 vs. lane 1) had little effect on the
phosphorylation of this protein. Relative to untreated cells, the phosphorylation
of Akt on Thr308 decreased with KU0063794 and DAPH (lanes 2-5 vs. lane 1)
but actually increased slightly in response to TMZ (lanes 7 and 8 vs. lane 7).
The phosphorylation of eIF2 was unaffected by KU0063794 (lanes 1-3) but
increased in the presence of DAPH and A769662, without or with TMZ present
(lanes 4-8 vs. lanes 1-3). Protein synthesis assays shown in Fig.5.7B
suggested that incubation of cells with KU0063794 resulted in an inhibition of
protein synthesis rates when compared to cells incubated without the
compound. These data are consistent with a central role for mTOR signalling in
controlling translation rates in U87-MG cells. Incubation of cells with DAPH also
inhibited radioactive methionine incorporation into protein but to a lesser extent.
This was also observed with DAPH in T98G cells (Fig.4.6). A769662 and TMZ
showed little effect on translation rates even though levels of
eIF2phosphorylation were increased over control cells.
5.3.8 Combining an mTOR inhibitor, TMZ and ionising radiation
dramatically reduces MGMT levels in T98G cells
The current strategy for treating GBM combines TMZ chemotherapy with
radiotherapy, for maximum efficacy. It was therefore important that I test the
compounds of interest with both TMZ and ionising radiation (IR) for effects on
signalling and MGMT protein levels. To this end, T98G cells were incubated for
72 hours with the compounds alone or in conjunction with TMZ, as specified in
Figure 5.8. Cells were then either transported to the gamma irradiator but not
irradiated, or irradiated with 2Gy of ionising radiation and allowed to recover for
24 hours before being harvested. I ensured that the cells which were not
irradiated spent the same amount of time outside the incubator as the ones that
were irradiated, so that this did not cause a difference in cell behaviour.
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Western blotting of cell extracts showed that the dephosphorylation of 4E-
BP1 is clear in cells incubated with KU0063794 (Fig.5.8A, lanes 5-7) whilst
there was little effect on Akt Thr308 phosphorylation. In contrast, there was a
robust increase in eIF2phosphorylation under these conditions and a
decrease in steady state levels of MGMT protein. Treatment of cells with IR
(lane 2), TMZ (lane 3) or IR with TMZ (lane 4) had no effect on either 4E-BP1 or
Akt Thr308 phosphorylation. However, the phosphorylation of eIF2 decreases
quite considerably under these conditions (lanes 2-4 vs. lane 1). DAPH or
A769662 treatment of cells did not elicit a dephosphorylation of 4E-BP1 under
any assay conditions, and generally lead to a slight decrease in Akt Thr308
phosphorylation (lanes 9-14 vs. lane 8). The reason for the increase in Akt
Thr308 phosphorylation in response to A769662 pus IR (lane 13) is unknown
and was not reproducible (data not shown). As there was a high basal level of
eIF2phosphorylation in the control extract here, it was impossible to see
whether there was any increase in phosphorylation; it certainly did not decrease
to the levels observed with A769662 (lanes 12-14 vs. lane 8). MGMT protein
levels are reduced in all treatments (lanes 9-12 and 14 vs. lane 8), again except
the A769662 plus IR treatment (lane 13). These dramatic changes seen in
MGMT protein levels in cells treated with all of the compounds are most likely
different from previous results because the cells have been in the treatment
plates for an extra 24 hours. Cytotoxicity assays were also difficult to execute in
parallel to these experiments, as cells need to be grown in 96 well plates for the
MTS assays, which can result in cells that are actively growing lacking space to
grow and therefore becoming apoptotic. Because of this, the changes in MGMT
levels, and the changes in eIF4A levels could be a result of cell death. The
effects on MGMT protein levels are also reflected by the [35S] methionine
incorporation data from the same treatments. All of the compound combination
treatments (again apart from the A769662 plus IR treatment) showed a large
decrease in protein synthesis rates (80-95% inhibition) relative to the untreated
cells. IR alone produced only a moderate inhibition of protein synthesis.
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5.4 Summary
 KU0063794 inhibits cap dependent translation by inhibiting mTORC1
and mTORC2 signalling
 Whilst DAPH is inhibiting cap dependent translation (but not as
effectively as KU0063794) it is also showing an effect on translation
elongation and MGMT mRNA levels
 A769662 is not affecting mTOR signalling, or cap dependent
translation. Although protein synthesis rates are increased, MGMT
protein levels are reduced
 The compounds are not sensitising the cells to TMZ treatment, as
there are still large amounts of MGMT protein within the cells.
However, MGMT protein levels do stabilise in the presence of
KU0063794, DAPH and A769662 when combined with TMZ compared
to MGMT protein levels in cells treated with the compounds alone.
5.5 Conclusions
A769662 and DAPH, when used alone are successfully reducing levels of
MGMT protein in T98G cells. However, the mechanism by which A769662 and
DAPH are doing this is not immediately obvious, and will have to be explored
further. MGMT protein levels are not affected to the same extent when any of
the three compounds are combined with TMZ. These data indicate that the
stability of the MGMT protein should be explored further. The experiment
exploring the affect of IR alone and when combined with both the compounds
and TMZ highlights another drawback (in addition to those mentioned earlier)
with the MTS assay; the small plate size and hence the area available for cells
to grow limits the duration of the experiments, especially with fast growing cells
such as T98G cells.
Chapter VI
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6 Exploring MGMT protein stability in T98G cells
6.1 Aims
 To determine the half-life of the MGMT protein in T98G cells
 To investigate the stability of MGMT protein in the presence of
KU0063794 versus KU0063794 and TMZ in T98G cells
6.2 Introduction
Temporarily inhibiting translation of MGMT as a means to improve the
efficacy of chemotherapy relies on the MGMT protein having a manageable half
life. The half life of MGMT protein had been previously recorded as 15-20 hours
in a different cell type [261]. It was important to ascertain the half life of MGMT
protein in T98G cells, to ensure that the combination treatments were being
administered in the most effective time frame. The experiments described in this
chapter were designed to inhibit the synthesis of MGMT in the cells and then
monitor the turnover of MGMT protein by Western blotting at different times after
incubation with or without KU0063794 and TMZ. These data would then give me
important mechanistic information regarding how the compounds used here
were affecting steady state MGMT protein levels.
6.3 Results
6.3.1 Cycloheximide inhibits protein synthesis in T98G cells
Temporarily inhibiting translation of MGMT as a means to improve the
efficacy of chemotherapy relies on the MGMT protein having a manageable half
life. The half life of MGMT protein had been previously recorded as 15-20 hours
in a different cell type [261]. It was important to ascertain the half life of MGMT
protein in T98G cells, to ensure that the combination treatments were being
administered in the most effective time frame. As a first step, I had to determine
which concentration of cycloheximide to use to inhibit protein synthesis in T98G
cells without causing cell death. As shown in Figure 6.1A, at least 0.5M was
required to inhibit protein synthesis; cells were still viable at this time (data not
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shown). To attempt to measure the half-life of MGMT, protein synthesis was
inhibited with 10M cycloheximide and cell extracts were prepared at different
times. Western blotting was then used to monitor the steady state level of
MGMT protein in these cells. Surprisingly, steady state levels of MGMT protein
apparently increased at later times of incubation (Fig.6.1B); this was repeated a
number of times (Panels C and D) with similar results. The reasons for this
apparent increase in protein level, even though translation rates are inhibited
(Panel A) were unclear.
6.3.2 Inhibition of mTOR signalling does not affect the half life of MGMT
protein in T98G cells but stabilises MGMT in the presence of TMZ
As cycloheximide generated inconclusive results, I repeated the experiments
using emetine, which also blocks translation elongation [262]. Cells were
incubated in the presence of emetine alone at a level sufficient to totally block
protein synthesis (data not shown; Fig.6.2A), or combined with KU0063794
(Panel B), TMZ (Panel C), or KU0063794 and TMZ together (Panel D). Cell
extracts were resolved by SDS-PAGE and MGMT levels visualised by Western
blotting. Fig 6.2A shows that MGMT protein is relatively stable in T98G cells,
with a half-life of approximately 60 hours (quantified in Panel E). This is
unchanged when cells are also incubated in the presence of KU0063794
(Panels B and E). However, incubation of cells with TMZ reduces the half-life of
MGMT in T98G cells to less than 12 hours (Panels C and E). This most likely
reflects the fact that MGMT is required for the repair of DNA damage induced by
TMZ and subsequently being proteolysed; as emetine is entirely blocking
protein synthesis, MGMT is unable to be re-synthesised to maintain steady state
levels (Panel C). Interestingly, inhibition of mTOR signalling with KU0063794
combined with emetine and TMZ restored steady state levels of MGMT when
added to cells (Panel D).
6.4 Summary
 The half-life of the MGMT protein in T98G cells is just under 72 hours
AFigure 6.1 Cycloheximide inhibits protein synthesis in T98G cells
Panel A. T98G cells were treated with different concentrations of cycloheximide for 24 hours 
and one hour prior to harvesting, cells were incubated with 10µCi/ml [35S] methionine, as 
described in Materials and Methods. Extracts were prepared and incorporation of radioactive 
methionine into protein determined as cpm/mg protein; results are presented as a % of the 
rate obtained in cells incubated in the absence of cycloheximide. Error bars are the S.D (n=3). 
A standard T Test was performed and p values were assigned limits where *<0.05, **<0.005 
and ***<0.001. Panel B. Cells were incubated in the absence (lane 1) or presence of 10mM 
cycloheximide (lanes 2-7) for 24 hours. Extracts were prepared and aliquots containing 10mg 
of protein were resolved by SDS-PAGE and proteins visualised by Western blotting using 
the antisera indicated. Panel C, D. Cells were treated as in (B) and incubated for the times 
indicated.
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Figure 6.2 Inhibition of mTOR signalling does not affect the half life of MGMT protein  
 in T98G cells but stabilises MGMT in the presence of TMZ
Panel A. T98G cells were incubated in the absence (lane 1) or presence of 10mM emetine 
alone  for up to 72 hours (lanes 2-4) Cells were also incubated in the absence or presence 
of 10mM KU0063794 and 10mM emetine (Panel B),10mM TMZ and 10mM emetine (Panel C) 
or 10mM KU0063794 and10mM TMZ and 10mM emetine (Panel D). Extracts were prepared 
and aliquots containing 10mg of protein were resolved by SDS-PAGE and proteins visualised 
by Western blotting using the antiserum indicated (n=2). Panel E. Data shown in Panels 
A-D was quantified using Image J software and the steady state level of MGMT protein ex-
pressed relative to eIF4A, with levels in untreated cells set at 100%.
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 KU0063794 is having a stabilising effect on the MGMT protein when
used to treat cells in combination with TMZ
6.5 Conclusions
These experiments clearly show that MGMT protein is relatively stable in
T98G cells, with a half-life of approximately 60 hours (quantified in Fig.6.2E). In
contrast to findings with TMZ, rates of MGMT turnover were unchanged when
cells were incubated in the presence of KU0063794. However, when used in
combination with TMZ, KU0063794 had a negative effect on MGMT protein
levels and inhibited the turnover of the protein. How this stabilisation occurs
remains unclear and should be the focus of more research, as MGMT can
prevent successful chemotherapy. Ideally, I would also liked to have measured
the synthesis rates of MGMT under these assays conditions as well. However,
the titre of the commercial antisera was insufficient to allow for
immunoprecipitation of the MGMT protein following pulse labelling of cells with
[35S] methionine (data not shown).
Chapter VII
Discussion
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7 Discussion
7.1 The chemicals derived from connectivity mapping effected the T98G
cells in different ways
The initial aim of my research was to use compounds to temporarily down-
regulate MGMT protein synthesis in T98G cells, whilst remaining non-toxic to
the cells. This down-regulation of MGMT protein would then create a window of
opportunity to treat the cells with the DNA methylating agent, TMZ. The cells
lacking MGMT would not be able to repair the damage caused by TMZ and so
the cells should acquire double-strand DNA breaks, arrest in the G2 phase of
the cell cycle and undergo apoptosis.
T98G cells were used as they over-express MGMT relative to other GBM cell
lines [258,259]. This was important as it gave me a good platform to study
MGMT protein levels and how they differed under a variety of treatment
regimes. It is important to take in to account that the some characteristics of
high grade glioma cells are unusual, due to genetic aberrations such as loss of
p53 and PTEN function, as well as EGFR amplifications [65–67], which could
cause compounds to have unusual effects in these cells, that may not have
been observed in other cell types.
It was important before beginning treatments, to ensure complete cell lysis
was effective, so as to get results during Western blotting that reflected protein
levels in the whole cell. When using an additional detergent in the lysis buffer,
there was not an increase in the recovery of MGMT protein (Fig.3.4). This may
be due to the T98G cells having weak nuclear membranes, causing the nuclei to
leak or rupture easily during the lysis procedure, even without detergent.
The initial drug treatments that I trialled were; direct inhibitors of mTOR
kinase activity (Torin1), mTORC1 complex inhibitors (rapamycin), or upstream
regulators of mTORC1 signalling (PI103, LY294002). Rapamycin inhibits
mTORC1 by forming a complex with FKBP12 which then binds to mTORC1 and
interacts with DEPTOR. Rapamycin inhibited protein synthesis in T98G cells at
10M levels (Fig.3.5B) and inhibited cell growth compared to untreated cells
over a 24 hour period (Fig.3.5C). However, Western blotting showed no effect of
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rapamycin on the phosphorylation status of 4E-BP1 and so the observed effect
of cell growth was unlikely to be a result of efficient inhibition of cap-dependent
translation initiation. It is possible that rapamycin was also inhibiting protein
synthesis via the phosphorylation of eIF2, as an increase was seen during
incubation of cells with rapamycin (Fig.3.2A). It has also been suggested that
mTORC1 interacts with GCN2, and inhibition of mTORC1 results in the
activation of GCN2, which in turn phosphorylates eIF2[263,264], thereby
inhibiting protein synthesis.
Torin 1 is a small molecule kinase inhibitor that directly inhibits mTOR
function [245]. It is therefore not surprising that a dephosphorylation of 4E-BP1
was observed after a 24 hour incubation of cells with Torin 1 and that protein
synthesis was decreased by 80% (Student’s t-test, p<0.001), indicating a
definite inhibition of signalling through mTORC1. Although both LY294002 and
PI103 are PI3K inhibitors, they differ in their relative selectivity. LY294002 is
specific for PI3K [242] but it will inhibit mTOR at high concentrations; PI103 is
not as specific as LY294002, in addition to mTOR, it also inhibits DNAPK [243].
Due to the hyperactivity of PI3K signalling in T98G cells occurring from the loss
of PTEN function [265,266], high doses of LY294002 were needed to inhibit
signalling through mTORC1 (Fig.3.6A) and reduce levels of protein synthesis
(Fig.3.9B). The broad inhibition of kinases in T98G cells incubated with PI103
was not desirable, as high concentrations were needed to inhibit mTORC1
signalling (Fig.3.7 A), and this resulted in cell cytotoxicity (Fig.3.9C).
The initial drug treatments outlined that an effective compound for inhibiting
the mTOR pathway would need to inhibit PI3K signalling. With this in mind, the
connectivity mapping algorithm was employed to find compounds that could
inhibit this pathways, without affecting non-specific targets. I used gene
signatures derived from rapamycin, LY294002 and custom gene list expression
profiles to find similar compounds. Interestingly, as well as producing positive
‘connections’ to PI3K and RTK inhibitors (Fig.4.1), positive ‘connections’ were
also found for dopamine (D2) receptor antagonists, sodium channel blockers
and corticosteroids. These classes of drugs recurred with the searches using
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the KU0063794 and A769662 gene signatures (Fig.4.2), and using the patient-
derived TMZ-resistant glioma data (Table 3.1). The dopamine receptor
antagonists revealed by the connectivity mapping mostly consisted of the
phenothiazene group of compounds. Although usually used as antipsychotics
[255,267], a member of this class of compounds (thioridazine) has recently been
re-popularised as a treatment for ovarian cancer [256]. It has been suggested
that dopamine antagonists influence Akt/mTOR signalling through the inhibition
of phosphorylation of both Akt and GSK3, effectively inhibiting mTORC1
signalling [268]. Corticosteroids have also been implicated in influencing mTOR
signalling [269], but only in a positive manner, suggesting that steroid
signalling/mTOR interactions have not been fully elucidated.
Each of the compounds that were identified from the connectivity mapping
experiments had previously been implicated in interacting with proteins
upstream of mTORC1. Resveratrol is a phytoalexin found in red grape skins and
the roots of Japanese knotweed, that can activate AMPK in some cell types
[270–272]. Even when T98G cells were incubated with resveratrol at high
concentrations, no effect was observed on mTOR signalling (Fig.4.3Band C).
However, a decrease in the number of cells in G1 phase of the cell cycle and an
increase in cells in S phase was observed in cells incubated with resveratrol for
24 hours (Fig.4.3D). This S phase arrest has also been observed in SW480
cells [273], but the cause remains unclear.
Beta escin (also known as escin or aescin) is a triterpenoid saponin that has
been isolated from the seed of the horse chestnut (Aesculus hippocastanum). It
has been shown to exhibit anti-edematous, anti-inflammatory, and anti-
carcinogenic properties in various disease models [274]. It has previously been
shown to inhibit Jak/Stat signalling in hepatocellular carcinoma cells through the
inhibition of Jak 1/2 and Stat3 [247]. This is interesting as the activation of Jak
can phosphorylate PI3K, therefore propagating signalling through the
PI3K/mTOR signalling pathway. However, during incubation with T98G cells,
beta escin was observed to be extremely toxic, even at low doses (Fig.4.4),
making it unsuitable for use in this circumstance, due to its cytotoxic and non
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specific effects. Thalidomide is a derivative of glutamic acid that is a well
characterised anti-emetic that caused undesirable and unpredicted teratogenic
effects in unborn babies during the 1970’s and was therefore withdrawn from
pharmaceutical use. This compound has recently been re-discovered as an
effective treatment for multiple myeloma [275], and also displays anti-angiogenic
and anti-inflammatory properties [276]. The anti-angiogenic properties of
thalidomide are thought to result from an inhibition of VEGF and FGF receptors
[277]; it is for this reason that this compound was of interest. Interestingly,
although inhibition of specific types of RTK has been demonstrated by
thalidomide in other cell types, thalidomide seemed to have little or no effect on
the T98G cells, even at high concentrations. This was not only true for MGMT
levels in the T98G cells, but also 4E-BP1 phosphorylation but also for the
methionine incorporation assays; when compared to untreated controls, the rate
of methionine incorporation into protein did not vary in cells incubated with
thalidomide (Fig.4.8B). These results could be reflecting that the main RTK
mutations in T98G cells are in EGFR and PDGFR (Fig.1.4), and that it is these
receptors that need to be inhibited specifically.
Thioridazine is a phenothiazene that has been widely used as an anti-
psychotic for many years [255]. In endometrial and cervical cell lines, new
research suggests that thioridazine effectively inhibits the PI3K/Akt/mTOR
signalling pathways [256], introducing the possibility that it could be used as a
novel anticancer agent. Thioridazine could be affecting the PI3K/Akt/mTOR
signalling pathway in these cells through the inhibition of the D2/3 dopamine
receptors. As mentioned before, mTOR signalling can be inhibited by D2/3
antagonists by preventing the phosphorylation of both Akt and GSK3, therefore
inhibiting mTORC1 signalling [268]. However, in contrast with the results
observed in other cell lines, T98G cells incubated with thioridazine showed no
inhibition of PI3K/mTOR signalling at a variety of times of incubation and
concentrations. There was a decrease in methionine incorporation into protein
compared to untreated controls, suggesting an inhibition of protein synthesis.
This could be accounted for by the increase in eIF2 phosphorylation that was
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observed in parallel to the inhibition of protein synthesis (Fig.4.9). The
phosphorylation of eIF2 may have been a resultant factor of ER stress brought
about by thioridazine, which has also been recently observed in other cell lines
[278]. ER stress can activate PERK, by the sequestering of the regulatory
chaperone GRP78 (BiP), which is usually bound to the ER lumen domain of the
eIF2 kinase, PERK. During cell stress, GRP78 binds preferentially to misfolded
proteins over the PERK ER domain. This allows PERK to homo-dimerise,
resulting in the phosphorylation and activation of the PERK cytoplasmic kinase
domain. This is then capable of phosphorylating the alpha subunit of eIF2,
resulting in the stabilisation of the eIF2-GDP-eIF2B complex, therefore
inhibiting formation of the initiation ternary complex, and the ribosomal
recruitment to mRNA which follows.
Each of the compounds derived from the connectivity mapping database
either directly or indirectly were incubated with T98G cells in different
concentrations for different amounts of time. This allowed me to monitor the
cells in different contexts, which gave me a broad overview of how the
compounds were affecting the cells. Based on these initial observations I had to
narrow down the compounds to a manageable amount. I used KU0063794 as a
positive control throughout my work as this was useful as a reference, but it also
produced some very interesting results. Figure 7.2 summarises how each of the
four final compounds could be affecting the mTOR signalling pathway.
The connectivity mapping database showed positive connections to a lot of
AMPK activators, such as resveratrol, so I also used a direct AMPK activator as
this fulfilled the criteria of affecting both PI3K signalling and mTOR signalling
through activation of TSC1/2 (Fig.7.2). DAPH was the only compound which
was directly predicted through the connectivity mapping technique, which I
chose to continue. This was due to it being a receptor tyrosine kinase inhibitor,
specific for EGFR, a truncated form of which is known to be specifically over-
expressed in GBM. The inhibition of EGFR also inhibits signalling through the
PI3K/mTOR and ERK1/2 signalling pathways. TMZ was also used in
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combination with these compounds, and alone, to identify if the compounds
were in fact sensitising the cells to TMZ through inhibition of MGMT.
A769662 is a compound in the thienopyridone family of drugs, that has been
shown to activate AMPK both via allosteric binding to the  subunit, and through
phosphorylation of the  subunit [279]. Contrary to the expected inhibitory effect
of A769662 on protein synthesis, I observed an increase in p70S6K Th389 and
Akt Thr308 phosphorylation accompanied with a lack of 4E-BP1
dephosphorylation. These data suggested that no inhibition of the mTOR
signalling pathway was taking place (Fig.4.5E). The protein synthesis data,
polysome profiles and m7GTP-Sepharose assays all supported this observation
further and actually suggested an increase in cellular protein synthesis in the
presence of A769662. These observations were also seen in U87-MG cells
which lack MGMT protein, making it unlikely that the mechanism of action is
entirely cell line specific. The most interesting effect that A769662 displayed in
my work was its ability to inhibit eIF2 phosphorylation in nutrient deprived cells
(Fig.5.8). During a 72 hour incubation of cells with both TMZ and  ray exposure,
all cells, including untreated controls, displayed an elevated phosphorylation of
eIF2This increase in phosphorylation could have been caused by amino acid
deprivation, as the cells were incubated in the same media for an extended
amount of time. However, the cells that were also incubated with A769662 did
not show this increased level of phosphorylation. This leads me to speculate
that A769662 causes an increase in mitochondrial function and therefore ATP
production. This would account for the positive effect observed in mTOR
signalling, and the increased rates of methionine incorporation into protein. The
unexpected effect on protein synthesis could be due to phosphorylated AMPK
simultaneously triggering mitophagy and the biogenesis of new mitochondria,
via the activation of PGC1, which is then responsible for the transcription of
mitochondrial genes [280].
DAPH is an RTK inhibitor that shows specificity for EGFR. It has also been
shown to effectively reverse fibril formation and therefore reduce the neurotoxic
effects often associated with Alzheimer’s disease [281]. Incubation of T98G and
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U87-MG cells with DAPH resulted in a slight, yet definite decrease in mTOR
signalling, and increased levels of 4E-BP1 dephosphorylation. Interestingly
there was also an 80% (Student’s t-test, p<0.005) decrease in methionine
incorporation into protein in T98G cells compared to untreated T98G cells.
However, the polysome analysis of cells incubated with DAPH for 24 hours
indicated a minimal loss of polysomes and a slight increase in 80S monosomes.
The presence of polysomes even with the massive decrease in translation rates
could possibly indicate ribosome stalling. Eukaryotic elongation factor 2 (eEF2)
has been shown to catalyse the translocation of peptidyl-tRNA from the A site to
the P site on the ribosome. It has been shown that phosphorylation of eEF2 at
Thr56 by eEF2 kinase inhibits its activity [282–285] and therefore causes
ribosome stalling. eEF2 can be dephosphorylated by mTORC1 signalling
through eEF2 kinase. Therefore the inhibition of mTORC1 could allow for eEF2
phosphorylation and promote ribosome stalling. In addition to an elongation
block, the increase in 80S monosomes is also indicative of a slight initiation
block, which is supported by the dephosphorylation of 4E-BP1.
TMZ is a methylating agent that creates methyl adducts on DNA, eventually
leading to replication fork collapse and double-strand DNA breaks. The halting
of the cell cycle in response to TMZ is primarily through p53 signalling, which
prevents CDK1/cyclin b complex formation and progression through the cell
cycle. However, cell cycle arrest was not observed in T98G cells incubated with
TMZ. This could be due to the lack of p53 in T98G cells due to a deletion
mutation, which is found in 38% of GBM tumours (Fig.1.4). Overall incubation
with TMZ alone had little effect on the T98G cells or the U87-MG cells, clearly
indicating that alone, this is not an effective treatment.
7.2 MGMT protein stability
KU0063794 directly inhibits the kinase activity of mTOR and therefore inhibits
the activity of both the mTORC1 and mTORC2 complexes (Fig.7.2). The effect
of KU0063794 on the mTOR signalling pathway is noticeable by both its
dramatic reduction in translation rates and the massive dephosphorylation of
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4E-BP1 that it causes. However, it was of significant interest that during long
incubation periods with KU0063794, levels of MGMT protein did not decrease.
This prompted questions about the half-life of the MGMT protein (and its
stability) in T98G cells. To determine the half-life of the protein, cells were
incubated with both the compound and the antibiotic, cycloheximide, which
inhibits translation elongation. When MGMT protein levels were measured by
Western blotting, there was an apparent dramatic rise in MGMT protein levels at
around 20 hours of incubation with the compound. The cell cycle of T98G cells
is also around 20 hours long, suggesting that the increase in MGMT could have
been due to the proliferation of cells as a result of lack of inhibition by
cycloheximide. During the incubation of T98G cells with cycloheximide, a shift in
MGMT protein size was also seen. Phosphorylation of MGMT at the Ser204
position has been observed in liver cells and this phosphorylation has been
shown to protect the protein from proteolytic digestion [286]. It is possible
therefore, that the shift seen in the Western blotting experiments may be due to
the phosphorylation and hence stabilisation of this protein. Further work would
be needed to investigate whether this was the case here.
7.3 MGMT translational regulation
In line with effects on translation initiation, polysome profile analysis of cells
treated with KU0063794 showed a stark reduction in actively translating
polysomes. Although some ribosomes were still actively involved in translation,
it was a massive reduction compared to untreated cells. This could indicate that
MGMT protein is being preferentially translated in the remaining polysomes, a
suggestion that becomes more interesting when looking at the structure of the
MGMT mRNA. MGMT mRNA has a very long 3’ UTR, which contains 3 possible
stem loop structures (Fig.7.1). It has been shown previously that some mRNAs
are translationally controlled by 3’ stem loop structures [287], so it is possible
that this is also the case for MGMT mRNA. To investigate if this could be the
case, quantitative RT-PCR was carried out on the fractions obtained from the
polysome profile analysis. The fractions were pooled into 4 categories, free
Figure 7.1 Diagram representing putative MGMT mRNA structural and regulatory 
 elements
The mature mRNA sequence for MGMT was entered in to RegRNA, a regulatory RNA 
motif and elements finder (developed by Huang et al., 2006). Possible structures were then 
identified by the program. The diagram illustrates secondary structures and motifs that may 
be of interest in future work. 
Figure 7.2 Schematic representation of mTOR signalling pathway and associated proteins
How the different compounds are possibly interacting with the mTOR signalling pathway in T98G cells. 
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material, subunits, light polysomes and heavy polysomes. As there are large
variations in the amount of RNA in each of these fractions, a standard
normalisation technique involving the expression of an abundant mRNA was not
possible (as was previously performed). Instead, I wanted to measure the shift
in MGMT mRNA between fractions, and compare that to the shift of a common
and abundant mRNA, GAPDH. It is important to note that although the amount
of RNA in each fraction changed between treatments, the total amount of RNA
across each gradient was similar, except for the amount of RNA in the cells
incubated with A769662, which showed an increase in total RNA concentration.
The qRT-PCR results displayed extremely interesting results, showing that
MGMT mRNA was present in heavy polysomes during incubation with each
compound. This observation was especially interesting for T98G cells incubated
with KU0063794 for 24 hours, as the amount of translating ribosomes were
greatly reduced compared to untreated cells, and GAPDH mRNA was present in
reduced amounts in both polysome fractions, and an increase was seen in the
subunit fractions. This shift in mRNA reinforces the suspected reduction in
actively translating ribosomes due to a block in initiation; secondary effects
could also reflect a possible reduction in ribosome biogenesis. However, during
these reduced translation rates in KU0063794 treated cells, MGMT mRNA was
still present at similar amounts to untreated cells in both heavy and light
polysomes, suggesting that it is in fact still being translated. An alternative
possibility if that the mRNA is present in stalled complexes or that it is present in
a protected form, such as a stress granule or a P body. As well as translational
regulation of the MGMT mRNA, protein expression could also be influenced by
transcription factor expression, miRNAs and methylation or acetylation of the
MGMT promoter.
7.4 Future work
This work highlights the importance of understanding the stability and
regulation of DNA repair proteins when considering approaches to cancer
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therapy. Understanding types of regulation is the only way a multifaceted
approach can be developed to modulate such proteins in the future.
The methylation of the MGMT promoter is by far the most commonly
mentioned type of regulation of MGMT protein expression [55,56,58,65,288–
290], yet this is not the only form. As mentioned in the section on protein
expression, alternative splicing of the pre-mRNA may also play a part in the
post-transcriptional regulation of MGMT. However, although alternative
predicted mRNA isoforms exist, regulation of MGMT at this level has not been
fully explored and generally lacks support in the scientific community [57]. I
explored the possibility that during reduced cap dependent translation, MGMT
mRNA is preferentially translated. Although I showed that MGMT mRNA
remains in polysomes during translation inhibition, these experiments need to
be further repeated. An EDTA control would also need to be performed to
ensure that the MGMT mRNA quantified was indeed in polysomes and not in a
protected form, such as an intracellular vesicle, P body or associated with a high
molecular weight protein complex.
The stability of a protein is also a very important factor to consider when
attempting to regulate its expression and/or degradation. During my research I
observed a shift in the size of MGMT protein during Western blot analysis.
Previous research suggests that this shift in size could be the result of cleavage
of the C-terminus of the MGMT protein [286]. Both cleavage and
phosphorylation of the MGMT protein have been suggested to increase its
resistance to proteolytic digestion [286]. However, this research is poorly
documented, and experiments directed at investigating this phenomenon should
be carried out. This could be investigated further using an antibody that is raised
against the C-terminus of the MGMT protein, and also by creating a specific
antibody for MGMT to study phosphorylation of the protein. Another way of
investigating the cleavage of the protein and ascertaining if this cleaved form is
present natively in cells would be to examine both an uncleaved MGMT protein,
and an artificially created MGMT protein lacking a C-terminus using X-ray
crystallography. Anan antibody could then be created that can only bind the
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MGMT isoform that lacks a C-terminus. This antibody could then be used to
study the stability of the protein, and if this changes during cell treatments
outlined in this thesis.
During my research, I used immortalised cell lines to study MGMT levels and
signalling pathways in GBM cells. However, there are marked differences in the
control of MGMT protein expression observed between clinical specimens and
cell lines, and this highlights the pitfalls of translating a cell line phenomenon
into a clinical procedure. As GBM cells are so heterogeneous, it would be
extremely interesting to ascertain the effect that chemical compounds, including
PI3K/mTOR signalling inhibitors had on primary cells derived from brain
tumours. Considering each cell in the GBM population could theoretically
express a different level of MGMT protein and have different underlying
mutations, this could be of considerable value to determine the percentage of
cells that could be sensitised to treatment, or not. The use of the compounds in
vivo would also be useful to determine their efficacy in sensitising cells to TMZ.
However, this would be complicated as obtaining ethics for experimental studies
involving human subjects, especially those that could be seen to be physically
and/or emotionally vulnerable is difficult.
When screening different chemical compounds for their effect on specific
proteins, high throughput methods could be extremely helpful. Antibody
conjugated fluorescent assays are now available that can quantify the amount of
many proteins in one sample in parallel. This minimises the need for the
quantification of Western blots, and the need for carrying out multiple identical
experiments with cell treatments to measure different protein phosphorylation
states and levels.
These are just some of the avenues that could be explored to clarify the role
of MGMT outside of its direct mechanism of action, which would be necessary
to fully understand its regulation, and hence modulate it for therapeutic
applications.
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7.5 Conclusions
The research presented here shows that regulating MGMT protein levels
through the inhibition of cap dependent translation using mTOR inhibitors is not
as effective as hypothesised. Signalling pathways, MGMT stability and genetic
mutations, all vary from one cell type to another. Therefore when tackling a
heterogeneous disease such as GBM, the treatments need to be carefully
tailored to the cell type, and the specific mutations most commonly seen in that
disease state need to be taken in to account. It is because of this that the only
way to tackle a disease that shows a plethora of aberrations is through a
combination of therapies, including ionising radiation, TMZ chemotherapy,
inhibition of hyperactive PI3K/Akt/mTOR signalling and inhibition of amplified
RTKs. This research also shows how important it is to identify how DNA repair
enzymes are transcribed and translated, as only then can they be manipulated
to aid in cancer treatment, instead of creating a barrier between treatment and
successful cancer elimination. This research also highlights the importance of
genetic profiling of tumours, to identify the most abundant cell types and
mutations within a tumour, to have the best chance of finding an effective
treatment.
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9 Appendices
Table A1. KU0063794 top 30 most changed genes
Gene Name log2 Fold Change Fold Change
ACPP 0.981268152 1.9742
ANKRA2 0.986884171 1.9819
ARHGAP15 1.023255352 2.0325
BCL6 1.009848767 2.013699999
BTG1 1.196166363 2.2913
C6orf66 -0.965784285 0.512
CABC1 0.968053878 1.956200001
CCNG2 2.062432604 4.1769
CDC25A -1.124062704 0.4588
CDR2L -1.012169823 0.4958
CYP1A1 1.509594508 2.847300001
EDN1 1.022261272 2.031100001
FZD9 -1.17722907 0.4422
HBP1 1.522909459 2.873699999
IFRD1 -0.958476638 0.5146
IRS2 1.353153885 2.554700001
KIAA0430 1.027861775 2.038999999
KLF9 1.011996488 2.0167
KLHL24 2.130799111 4.3796
MAP6D1 -1.025030237 0.4914
MRPS12 -1.143054137 0.4528
MYC 0.978634962 1.9706
P2RY2 -1.236843416 0.4243
124
PHLDA2 -1.09819665 0.4671
PUS1 -0.966066089 0.5119
SLC38A2 1.004393523 2.0061
SOCS2 1.210949873 2.3149
SRPK2 1.443606651 2.719999999
TXNIP 1.066881379 2.094900001
YPEL5 0.992695932 1.9899
Table A2. A769662 top 30 most changed genes
Gene Name log2 Fold Change Fold Change
CYP1A1 0.804714436 1.7468
C1orf25 0.547844628 1.4619
IFI6 0.540324906 1.4543
S100P 0.520749097 1.4347
CCNG2 0.456806149 1.3725
PTGER4 0.439250781 1.3559
SAT1 0.418135964 1.3362
ALDH1A3 0.412076939 1.3306
ACACB 0.40729836 1.3262
TAF1C 0.401958066 1.3213
VPS13A 0.3950628 1.315
BNIP3 0.379620962 1.301
HERC5 0.377512488 1.2991
FGD1 0.377068206 1.2987
PRR3 -0.382513434 0.7671
PKN1 -0.382701517 0.767
HMOX1 -0.384018789 0.7663
125
CIAO1 -0.384772056 0.7659
SPG21 -0.385714194 0.7654
SAPS1 -0.397448103 0.7592
MRPS12 -0.402969476 0.7563
TRIM16 -0.407937702 0.7537
NSUN5 -0.411003598 0.7521
WDR43 -0.411195433 0.752
GNA11 -0.425462479 0.7446
COQ6 -0.465141549 0.7244
MOCS2 -0.47252925 0.7207
SCRIB -0.49228146 0.7109
OGFRL1 -0.50021788 0.707
RPL39L -0.531156057 0.692
Table A3. Top 40 raw connections for KU0063794
Reference set name Refere
nce set
score
sirolimus_0.1muM_6h_MCF7_human_Affy 13.922
58
LY-294002_10muM_6h_MCF7_human_Affy 11.109
76
trifluoperazine_10muM_6h_MCF7_human_Affy 9.7756
58
LY-294002_10muM_6h_PC3_human_Affy 9.4538
88
sirolimus_0.1muM_6h_PC3_human_Affy 9.2613
126
07
wortmannin_10nM_6h_MCF7_human_Affy 8.9468
53
fluphenazine_10muM_6h_MCF7_human_Affy 8.8630
23
wortmannin_1muM_6h_MCF7_human_Affy 8.6915
07
benzamil_11.2muM_6h_PC3_human_Affy 7.1786
59
quinostatin_10muM_6h_MCF7_human_Affy 7.1112
33
thioridazine_9.8muM_6h_MCF7_human_Affy 7.0134
87
perhexiline_10.2muM_6h_MCF7_human_Affy 7.0115
83
mefloquine_9.6muM_6h_MCF7_human_Affy 6.9128
48
valinomycin_0.1muM_6h_PC3_human_Affy 6.8300
11
5707885_50muM_6h_PC3_human_Affy 6.7357
66
benzamil_11.2muM_6h_MCF7_human_Affy 6.6889
61
prochlorperazine_10muM_6h_MCF7_human_Affy 6.6766
52
methylbenzethonium
chloride_8.6muM_6h_MCF7_human_Affy
6.6447
83
latamoxef_7muM_6h_MCF7_human_Affy 6.5958
5
tetrandrine_6.4muM_6h_MCF7_human_Affy 6.5400
127
84
pyrvinium_3.4muM_6h_MCF7_human_Affy 6.4524
94
wortmannin_10nM_6h_PC3_human_Affy 6.3403
7
fluphenazine_10muM_6h_PC3_human_Affy 6.3129
09
colforsin_50muM_6h_MCF7_human_Affy 6.3113
3
tribenoside_8.4muM_6h_MCF7_human_Affy 6.3070
69
thioridazine_10muM_6h_MCF7_human_Affy 6.1690
52
ticlopidine_13.4muM_6h_MCF7_human_Affy 6.0197
36
rottlerin_10muM_6h_MCF7_human_Affy 5.8443
06
meclozine_8.6muM_6h_MCF7_human_Affy 5.8387
59
prenylamine_9.6muM_6h_MCF7_human_Affy 5.8079
41
valinomycin_0.1muM_6h_MCF7_human_Affy 5.7836
89
chlorcyclizine_11.8muM_6h_MCF7_human_Affy 5.7453
49
resveratrol_10muM_6h_MCF7_human_Affy 5.7330
7
troglitazone_10muM_6h_MCF7_human_Affy 5.7232
15
trifluoperazine_10muM_6h_PC3_human_Affy 5.6245
128
48
phenazopyridine_16muM_6h_MCF7_human_Affy 5.6223
87
cloperastine_11muM_6h_MCF7_human_Affy 5.6080
1
wortmannin_10nM_6h_HL60_human_Affy 5.4452
46
thioridazine_10muM_6h_HL60_human_Affy 5.3712
87
calmidazolium_5muM_6h_MCF7_human_Affy 5.3690
66
Table A4. Top 40 raw connections for A769662
Reference set name Refere
nce set
score
sirolimus_0.1muM_6h_MCF7_human_Affy 5.3613
76
thioridazine_10muM_6h_HL60_human_Affy 4.9094
57
colforsin_50muM_6h_MCF7_human_Affy 4.8713
03
LY-294002_10muM_6h_MCF7_human_Affy 4.7154
55
corynanthine_10.2muM_6h_MCF7_human_Aff 4.5539
129
y 68
mepacrine_7.8muM_6h_MCF7_human_Affy 4.5060
69
prochlorperazine_10muM_6h_MCF7_human_
Affy
4.3865
18
benserazide_13.6muM_6h_PC3_human_Affy 4.3790
1
thioridazine_10muM_6h_MCF7_human_Affy 4.3439
61
antimycin A_7.2muM_6h_MCF7_human_Affy 4.2257
99
deferoxamine_0.1mM_6h_MCF7_human_Affy 4.2150
92
lanatoside C_4muM_6h_MCF7_human_Affy 4.1666
14
LY-294002_10muM_6h_PC3_human_Affy 4.1594
72
scriptaid_10muM_6h_PC3_human_Affy 4.1527
82
ambroxol_9.6muM_6h_PC3_human_Affy 4.1343
36
rescinnamine_6.4muM_6h_MCF7_human_Affy 4.1287
98
5707885_50muM_6h_MCF7_human_Affy 4.1077
51
acepromazine_9muM_6h_PC3_human_Affy 4.0975
82
fluphenazine_10muM_6h_MCF7_human_Affy 4.0660
56
fusaric acid_22.4muM_6h_MCF7_human_Affy 3.9281
130
46
protriptyline_13.4muM_6h_MCF7_human_Affy 3.8840
98
trifluoperazine_10muM_6h_MCF7_human_Aff
y
3.8758
45
cloperastine_11muM_6h_MCF7_human_Affy 3.7913
21
latamoxef_7muM_6h_MCF7_human_Affy 3.7222
22
orciprenaline_7.6muM_6h_HL60_human_Affy 3.7187
9
desipramine_13.2muM_6h_MCF7_human_Aff
y
3.6811
11
cisapride_8.6muM_6h_PC3_human_Affy 3.6685
51
remoxipride_9.8muM_6h_HL60_human_Affy 3.6355
93
helveticoside_7.4muM_6h_MCF7_human_Affy 3.6311
92
sirolimus_0.1muM_6h_PC3_human_Affy 3.6302
54
dimethadione_31muM_6h_PC3_human_Affy 3.6294
35
cefoperazone_5.8muM_6h_HL60_human_Affy 3.5781
97
AG-013608_10muM_6h_MCF7_human_Affy 3.5556
38
liothyronine_6.2muM_6h_PC3_human_Affy 3.5501
81
tetryzoline_16.8muM_6h_HL60_human_Affy 3.5376
131
94
0175029-0000_1muM_6h_MCF7_human_Affy 3.5267
9
prenylamine_9.6muM_6h_MCF7_human_Affy 3.5116
28
fulvestrant_1muM_6h_MCF7_human_Affy 3.5003
92
alprostadil_11.2muM_6h_HL60_human_Affy 3.4862
87
dl-alpha
tocopherol_9.2muM_6h_PC3_human_Affy
3.4173
29
Figure A5. Helicase assay
1.Resveratrol, 2.Thalidomide, 3.Beta escin, 4.Spiperone, 5.DAPH,
6.KU0063794, 7.A769662.
132
CTCGGCCCCGCCCCCGCGCCCCGGATATGCTGGGACAGCCCGCGCCCCTAGAACGCTTTGCGTCCCGACG
CCCGCAGGTCCTCGCGGTGCGCACCGTTTGCGACTTGGTACTTGGAAAAATGGACAAGGATTGTGAAATG
AAACGCACCACACTGGACAGCCCTTTGGGGAAGCTGGAGCTGTCTGGTTGTGAGCAGGGTCTGCACGAAA
TAAAGCTCCTGGGCAAGGGGACGTCTGCAGCTGATGCCGTGGAGGTCCCAGCCCCCGCTGCGGTTCTCGG
AGGTCCGGAGCCCCTGATGCAGTGCACAGCCTGGCTGAATGCCTATTTCCACCAGCCCGAGGCTATCGAA
GAGTTCCCCGTGCCGGCTCTTCACCATCCCGTTTTCCAGCAAGAGTCGTTCACCAGACAGGTGTTATGGA
AGCTGCTGAAGGTTGTGAAATTCGGAGAAGTGATTTCTTACCAGCAATTAGCAGCCCTGGCAGGCAACCC
CAAAGCCGCGCGAGCAGTGGGAGGAGCAATGAGAGGCAATCCTGTCCCCATCCTCATCCCGTGCCACAGA
GTGGTCTGCAGCAGCGGAGCCGTGGGCAACTACTCCGGAGGACTGGCCGTGAAGGAATGGCTTCTGGCCC
ATGAAGGCCACCGGTTGGGGAAGCCAGGCTTGGGAGGGAGCTCAGGTCTGGCAGGGGCCTGGCTCAAGGG
AGCGGGAGCTACCTCGGGCTCCCCGCCTGCTGGCCGAAACTGAGTATGTGCAGTAGGATGGATGTTTGAG
CGACACACACGTGTAACACTGCATCGGATGCGGGGCGTGGAGGCACCGCTGTATTAAAGGAAGTGGCAGT
GTCCTGGGAACAAGCGTGTCTGCCCTTTCTGTTTCCATATTTTACAGCAGGATGAGTTCAGACGCCCGCG
GTCCTGCACACATTTGTTTCCTTCTCTAACGCTGCCCTTGCTCTATTTTTCATGTCCATTAAAACAGGCC
AAGTGAGTGTGGAAGGCCTGGCTCATGTTGGGCCACAGCCCAGGATGGGGCAGTCTGGCACCCTCAGGCC
ACAGACGGCTGCCATAGCCGCTGTCCAGGGCCAGCTAAGGCCCATCCCAGGCCGTCCACACTAGAAAGCT
GGCCCTGCCCCATCCCCACCATGCCTCCCTTCCTGGCTGTGTCCATGGCTGTGATGGCATTCTCCACTCA
GCAGTTCCTAGCATCCCACACCCAGGTCTCACTGAAAGAAAGGGGAACAGGCCATGGCAGTCAGTGCTTA
CAGAG
Figure A6. MGMT mRNA sequence
